Spenser Lin No Comments

Healthcare News, Deals, and Investments Update October 5th, 2026

LECO_Weekly-Healthcare-News_10-05-2026Download

Healthcare Weekly News and Deals – Oct 5th, 2026

  1. Smart ring maker Oura has postponed its Nasdaq IPO, which would have raised up to $2.2 billion through the sale of 50 million shares, citing uncertainty in the listing market just eight days after formally launching the process. Oura delayed its planned Nasdaq listing despite what it described as strong demand and a strengthening of the business since the IPO process began. The company launched its plans on September 21 and had intended to raise up to $2.2 billion by selling 50 million shares. CEO Tom Hale said Oura aims to deliver an extraordinary IPO for employees and investors and has “the luxury of choosing our moment.” Oura says it is profitable, with revenue expected to grow 90% year over year in fiscal 2026. It follows Holtec Nuclear’s withdrawal earlier in the month. (Link)
  2. U.S. healthcare technology investor Thoreau has committed $500 million to launch Ortet, a frontier AI lab for health building models that connect patient biology, treatment and healthcare administration. Ortet launched on September 29, 2026 with a $500 million commitment from Thoreau, bringing together former drug industry and technology company researchers. The company plans to use the backing to build computing and data infrastructure, train and deploy health-focused models, and recruit researchers and engineers. Ortet has already secured an initial cluster of graphics processing units, the specialized chips used to train and run AI systems. Rather than targeting a single clinical task, the lab is building models intended to link patient biology, treatment and healthcare administration, making it one of the largest single capital commitments to a healthcare AI company at formation. (Link)
  3. Grindr (NYSE:GRND) has agreed to acquire PurposeMed, the parent company of HIV-prevention telehealth provider Freddie, in a $250 million cash-and-stock deal with up to $70 million of additional performance consideration. Grindr will pay $190 million in cash and $60 million in common stock for PurposeMed, with up to $70 million in further cash tied to Freddie’s 2027 performance and payable in 2028. The transaction is expected to close in the fourth quarter and is Grindr’s first major acquisition since its 2009 founding. CEO George Arison said the healthcare line could become as profitable and as large as the core business, and that building it internally would have taken two to three years. Grindr expects the combined U.S. telehealth and pharmacy business to generate more than $400 in monthly revenue per active patient, implying roughly $240 million of annual revenue at 50,000 patients. (Link)
  4. Inogen (NASD: INGN) has agreed to divest its U.S. oxygen rental business to national home respiratory provider Rotech Healthcare for estimated cash consideration of up to $25 million. Inogen (INGN) signed a definitive agreement to sell specified U.S. oxygen rental assets to Rotech Healthcare for total estimated cash consideration of up to $25 million, with closing expected in the fourth quarter of 2026. The rental business generated $24.3 million of revenue in the first half of 2026, a 9.8% year-over-year decline, and will be presented as discontinued operations beginning in Q3. Inogen expects the transactions to increase both its revenue growth rate and adjusted operating income. Subject to closing, the board approved a $15 million increase to the share repurchase authorization, taking it to $45 million through June 2028. (Link)
  5. Interpace Biosciences (IDXG) has filed terms for a $20 million offering of 3.1 million shares at an assumed $6.47 per share to support a proposed uplisting from OTC to Nasdaq. Interpace Biosciences (IDXG), the Parsippany, New Jersey molecular diagnostics company behind the ThyGeNEXT and ThyraMIR v2 thyroid tests, filed terms on September 25, 2026 for a $20 million deal covering 3.1 million shares at an assumed $6.47; the offering remains unpriced. The raise follows an August reverse stock split announced to support the proposed Nasdaq uplisting. Thyroid test volume rose from 25,200 in 2022 to 36,200 in 2025 and pro forma revenue grew from $20.3 million to $34.8 million, a 19.7% CAGR, after the company stopped accepting PancraGEN specimens in May 2025 following a loss of CMS reimbursement. (Link)
  6. KALA Bio (NASD: KALA) has signed a non-binding letter of intent to acquire 100% of a privately held U.S. telehealth management services organization for approximately $15 million in cash and KALA stock. KALA Bio (KALA) signed the LOI on September 24, 2026 for an MSO supporting a LegitScript-certified, NABP-accredited provider-led telehealth platform operating in all 50 states across GLP-1 weight management, hormone health, longevity and sexual wellness. The target generated roughly $12.7 million of unaudited revenue for the trailing twelve months ended August 2026, over $48 million of sales since its 2023 founding, has served more than 90,000 clients and is described as cash-flow positive. The cash portion would come from existing balance sheet resources, with closing targeted for late 2026 or early 2027. (Link)
  7. SpyGlass Pharma (NASD: SGP) has acquired Advanced Vision Science from Santen for about $13 million in cash. Advanced Vision Science has made intraocular lenses since 1975 and supplies Santen’s Eternity lens in Japan. It also licenses glistening-free hydrophobic acrylic material to Bausch + Lomb for the enVista line. Those supply and license arrangements stay in place. SpyGlass, which is developing a drug-pad lens implanted during cataract surgery for glaucoma, is buying the plant to secure commercial lens supply. (Link)
  8. Shionogi has agreed to acquire Austin-based IntraBio for $2.0 billion, adding the rare-disease therapy AQNEURSA. Shionogi is buying all outstanding shares of IntraBio, an Austin company founded in 2015, for $2.0 billion in upfront cash. IntraBio sells AQNEURSA, approved in the United States and Europe for neurological symptoms of Niemann-Pick disease type C and, as of September 18, for ataxia in ataxia-telangiectasia in the United States. The company becomes a subsidiary of Shionogi’s New Jersey unit. Closing is scheduled for November or December, subject to antitrust review. Shionogi bought the RADICAVA ALS franchise in April. (Link)
  9. AstraZeneca has agreed to invest $2 billion in newly issued equity of Summit Therapeutics (NASD: SMMT), taking about a 12 percent stake. AstraZeneca is buying convertible preferred equal to about 12 percent of Summit’s common stock, or 10.6 percent fully diluted. The stake sits alongside a clinical collaboration testing AstraZeneca’s Claudin-18.2 antibody-drug conjugate, sonesitatug vedotin, with Summit’s PD-1/VEGF bispecific ivonescimab in gastrointestinal cancers. Each company keeps rights to its own drug. The investment was announced September 29 and was expected to close within about a week. (Link)
  10. GE HealthCare (NASD: GEHC) has agreed to acquire SOFIE Biosciences from Trilantic North America for $945 million in cash. SOFIE is a U.S. contract manufacturer for PET radiopharmaceuticals, with 15 sites, 21 cyclotrons and a theranostics development site, plus U.S. rights to FAPI-74, a Phase III PET tracer aimed at pan-cancer imaging. The business will sit in GE HealthCare’s pharmaceutical diagnostics segment and gives the buyer a last-mile network for short-lived tracers. Closing is aimed at the first half of 2027, subject to regulatory approval. (Link)
  11. Lantern Pharma (NASD: LTRN) has agreed to sell 3,669,725 shares at $1.09 in a registered direct offering raising approximately $4 million, with up to $4 million more available from concurrent private placement warrants. Lantern Pharma (LTRN), a clinical-stage AI-native precision oncology company, entered a definitive agreement for a registered direct offering of 3,669,725 shares, or pre-funded warrants in lieu, priced at $1.09 each. Aggregate gross proceeds are expected to be about $4 million. In a concurrent private placement, investors receive unregistered warrants over an equal number of shares at a $1.09 exercise price, exercisable only after stockholder approval and expiring five years later; full cash exercise would add roughly $4 million. Closing was expected on or about September 30, 2026, with proceeds earmarked for working capital and general corporate purposes. (Link)
  12. Leica Biosystems, a Danaher (NYSE: DHR) company, has completed its acquisition of pre-analytical consumables maker StatLab Medical Products from private equity owners Linden Capital Partners and Audax Private Equity. Danaher (DHR) subsidiary Leica Biosystems completed its purchase of privately held StatLab Medical Products on September 28, 2026, acquiring the business from Linden Capital Partners and Audax Private Equity. Terms were not disclosed. The deal extends Leica’s end-to-end anatomic pathology portfolio across specimen collection and preparation, advanced staining, digital imaging and AI-enabled diagnosis. Management positioned the combination as a response to laboratories facing rising case volumes, increasing complexity and staffing pressure, and as support for Leica’s biopharma partnerships within Danaher’s connected diagnostics ecosystem. (Link)
  13. Goldman Sachs (NYSE: GS) and Charlesbank Capital Partners-backed MyEyeDr. has agreed to acquire the 300-plus office optometry division of Partners Group (SWX: PGHN)-owned EyeCare Partners for an undisclosed sum. MyEyeDr., backed by Goldman Sachs (GS) and Charlesbank Capital Partners, is buying EyeCare Partners’ optometry division, which spans more than 300 offices under the Clarkson Eyecare, EyeCare Associates, EyeCare Center, Nationwide Vision and The Eye Doctors brands. Partners Group (PGHN) acquired EyeCare Partners in a $2.2 billion deal in late 2019, while Goldman Sachs bought MyEyeDr. for $2.7 billion the same year; MyEyeDr. already runs roughly 1,000 locations across about 30 states. EyeCare Partners will apply proceeds to reduce debt and strengthen liquidity while focusing on ophthalmology and ambulatory surgical centers. Closing is expected in Q4 2026. (Link 1) (Link 2)
  14. APM Group has agreed to acquire occupational health provider Medcor, combining it with previously acquired WorkCare and its Assure employee assistance business into a 2,000-employee North American platform. APM Group announced on September 28 that it entered an agreement to acquire Medcor, subject to Federal Trade Commission approval, with financial terms and completion date undisclosed. The deal follows APM’s April acquisition of WorkCare. Combined with Assure, the three businesses would employ more than 2,000 people across 450 sites, with services in every U.S. state and territory and every Canadian province. The combined portfolio spans injury prevention, onsite medical services, occupational health screenings, injury triage, telehealth, case management, return-to-work support and mental health services. Medcor, founded in 1984, adds mobile occupational health and 24/7 telehealth. (Link)
  15. Flexpoint Ford has sold behavioral health pharmacy platform ArtesRx — a business it co-founded in 2023 with Dom Meffe — to healthcare specialist Linden Capital Partners. Flexpoint Ford announced the sale of ArtesRx to Linden Capital Partners for undisclosed terms, a sponsor-to-sponsor exit of a platform Flexpoint built from scratch just three years ago. ArtesRx, established in 2023 by Flexpoint and Dom Meffe, is a behavioral health pharmacy platform serving individuals who depend on complex medication regimens. Chicago-based Flexpoint, founded in 2005, writes $50 million to $500 million per transaction across minority and majority structures in both private and public companies. Linden, also Chicago-based and founded in 2004, invests exclusively in healthcare across services, products and distribution and prefers larger cheques. (Link)
  16. Charlesbank Capital Partners and Warburg Pincus-backed MB2 Dental has partnered with Honolulu-based Hawaii Pacific Dental Group in its 14th acquisition of 2026. MB2 Dental, the Dallas dental support organization backed by middle-market private equity firm Charlesbank Capital Partners and growth equity investor Warburg Pincus, formed a strategic partnership with Hawaii Pacific Dental Group. The Honolulu practice, led by Dr. Rohinton J. Patel, provides cosmetic, restorative, preventative and family dentistry. MB2 supports a nationwide network of more than 1,900 affiliated physicians and practice partners across general dentistry, orthodontics, cosmetic care and oral surgery. The transaction expands MB2’s footprint across Hawaii and the broader Pacific region and marks its 14th acquisition of 2026. Financial terms of the private transaction were not disclosed. Link (Link)
  17. Standard Dental Labs (OTCQB: TUTH) has acquired substantially all operating assets of Dr. Tooth, LLC — also known as Sheen Dental Laboratory and Hansen Incarnati — in a cash-and-stock asset purchase with earnout conditions. Standard Dental Labs (TUTH) closed the acquisition effective October 2, 2026, structured as an asset purchase combining cash and SDL common stock with performance conditions tied to retained customer revenue. Management estimates the acquired business adds just over $800,000 in annualized revenue, taking SDL’s estimated annualized base above $1.6 million and nearly doubling the prior estimate. SDL plans to move production to its Sarasota facility, reshoring work currently outsourced to China to lift utilization and facility profitability. Management believes the business can be rebuilt to more than $1.1 million in annualized revenue. (Link)
  18. Banner Capital, with healthcare private equity firm Seventeen Capital as strategic co-investor, has agreed to acquire Seaway Plastics Engineering, MME Group and Wright Engineered Plastics, forming medical device manufacturing platform Seaway Group under Executive Chairman Ron Labrum. Salt Lake City-based Banner Capital formed Seaway Group and entered a definitive agreement to acquire the three medical device contract manufacturers, with closing expected in the fourth quarter of 2026. Seventeen Capital, a healthcare private equity firm led by medical device executive Ron Labrum, is a strategic co-investor, and Labrum becomes Executive Chairman at close. Seaway Group is the third platform in Banner Capital Fund II, after Western Pavement Services and Roof Restoration Group. Banner targets founder-led Western U.S. businesses with $4 million to $15 million of EBITDA and managed $611 million as of June 30, 2026. (Link)
  19. Wandercraft has acquired Ekso Bionics from a subsidiary of ChronoScale Holdings (NASD: CHRN), uniting two medical exoskeleton pioneers into a global robotic mobility platform. Wandercraft acquired Ekso Bionics from a ChronoScale Holdings (CHRN) subsidiary in a transaction unanimously approved by both boards and signed and closed simultaneously; financial terms were not disclosed. The combination pairs Wandercraft’s advanced robotics, physical AI and EMEA leadership with Ekso’s U.S. presence, clinical evidence base and commercial reach. Atalante X and EksoNR support patients at more than 700 rehabilitation centers worldwide, with FDA clearances and CE marking covering stroke, spinal cord injury, multiple sclerosis and acquired brain injury, while Eve and Indego Personal address at-home mobility. Wandercraft will continue supporting all four products. (Link)
  20. The University of Kansas Health System has agreed to take full ownership of the St. Francis campus in Topeka from Ardent Health (NYSE: ARDT). The two have run St. Francis and affiliated Topeka sites as a joint venture since 2017, after the campus had been facing closure. Ardent has handled day-to-day operations. KU Health System has provided clinical and financial support. Ardent will stay involved for a period after closing. The transfer is expected by the end of 2026, subject to approvals. (Link)
  21. Biospring Partners has led a growth investment in CDMO Serán Bioscience alongside existing investors Vivo Capital and Bain Capital Life Sciences to fund a new commercial spray-drying facility in Bend, Oregon. Biospring Partners led the growth investment with continued participation from Vivo Capital, Bain Capital Life Sciences and Serán’s executive leadership. Proceeds support a greenfield commercial manufacturing facility on track for completion in Q3 2027, creating an integrated 200,000-plus square foot campus with OEB4 manufacturing, spray drying, nano-milling and finished-dose capabilities. Biospring, founded in 2020, is a healthcare growth buyout firm with more than $500 million under management focused on pharma services; Vivo manages roughly $5.8 billion. Serán employs over 200 people and plans up to 150 additional hires. (Link)
  22. Renovus Capital Partners portfolio company TJP has acquired life sciences market research firm Evolution Consulting & Research, completing an end-to-end research, strategy, creative, pull-through and analytics platform for pharma clients. TJP, a Conshohocken, Pennsylvania value and patient access agency owned by Renovus Capital Partners, acquired Evolution Consulting & Research. The add-on follows TJP’s earlier purchase of FX2 Virtual and gives clients continuity from upfront market research through strategy, creative, virtual field execution and analytics. CEO Rino Mariconda, also an operating partner at Renovus, said the deal fulfills the firm’s vision of a unified platform. Renovus, founded in 2010, invests in knowledge and talent industries including healthcare and life sciences services, and builds platforms through operational improvement and add-on acquisitions. Terms were undisclosed. (Link)
  23. Resonant Clinical Solutions has acquired Hamburg-based labfish rental solutions GmbH and its U.S. and U.K. affiliates, expanding its Equipment & Ancillaries business across Europe. Resonant Clinical Solutions, a Leesburg, Virginia clinical supply chain and sample lifecycle partner, acquired Labfish together with its U.S. and U.K. affiliates for undisclosed terms. Labfish rents scales, freezers, refrigerators, infusion pumps and monitors, supplies kitting and ancillaries, and operates one of the largest in-house calibration facilities serving clinical trials in Europe. It also provides Importer and Exporter of Record services and direct-to-patient logistics, working with partner depots in Argentina, Israel, Turkey and China to supply sites in more than 70 countries. Resonant has over 850 employees and has supported more than 2,500 clinical trials. (Link)
  24. Sheridan Capital Partners has acquired Durham, North Carolina-based single-use bioprocessing components supplier Carolina Components Group, its fourth platform acquisition of 2026. Chicago healthcare private equity firm Sheridan Capital Partners acquired Carolina Components Group, a 2020-founded supplier of ultra-pure components, custom-engineered single-use assemblies and process solutions serving more than 250 biopharmaceutical and contract manufacturing customers. CCG operates over 100,000 square feet of ISO Class 7 and Class 8 cleanroom and manufacturing space, scale Sheridan says regional competitors lack. Sheridan cited CCG’s supplier-agnostic model and its status as a founder-owned business at a growth inflection point. The deal is Sheridan’s fourth of 2026 after ICANotes, Tres Health and PtEverywhere. (Link)
  25. Chicago Pacific Founders has exited veterinary AI company CoVetAI following its acquisition by IDEXX Laboratories (NASD: IDXX), the first realization from CPF’s Pet Fund – Off Leash Capital. IDEXX Laboratories (IDXX) acquired CoVetAI, developer of an AI-powered clinical scribe and workflow platform for veterinary medicine, handing Chicago Pacific Founders the first realization from its specialist animal health fund. Financial terms were not disclosed. CPF was CoVet’s sole institutional investor and backed the company from an early stage; Pet Fund partner Gina Del Vecchio described IDEXX as the ideal owner to scale the product globally. The fund closed on September 16, 2026, holds six portfolio investments, and targets a companion animal market currently worth $288.4 billion and projected to reach $560.7 billion by 2034. (Link)
  26. Brady (NYSE: BRC) has sold its French first-aid business Securimed to Safe Life for about $59 million. Securimed, based in Cappelle-la-Grande, sells customized first-aid kits, protective equipment and emergency-response products, mostly to corporate health and safety departments in France. Brady bought the business in 2010. The price is about €53 million. Brady is an identification and safety-products company based in Milwaukee and is treating the unit as outside that core. (Link)

Venture Deals and Other

  1. Anthropic, PBC has confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock, with share count and price not yet set. Anthropic, PBC confidentially submitted a draft Form S-1 to the SEC for a proposed initial public offering of its common stock. The submission gives the AI developer the option to go public once the SEC completes its review, with any offering dependent on market conditions and other factors. The number of shares to be offered and the price have not yet been set. The announcement was published under Rule 135 of the Securities Act of 1933 and is not an offer to sell or a solicitation of an offer to buy securities. No valuation, timetable, exchange or selling shareholders were disclosed. (Link 1) (Link 2)
  2. Lux Capital and Natural Capital have co-led a $251 million Series D in El Segundo-based in-orbit pharmaceutical processing company Varda Space Industries, joined by Founders Fund, Khosla Ventures, Caffeinated Capital, General Catalyst, 8090 Industries, Giant Step and Also Capital, at a $1.6 billion valuation. Lux Capital and Natural Capital led Varda Space Industries’ $251 million Series D, with Founders Fund, Khosla Ventures, Caffeinated Capital, General Catalyst, 8090 Industries, Giant Step and Also Capital participating. The round values the microgravity-enabled life sciences company at $1.6 billion and lifts total capital raised to $598 million. Varda has completed six reentry missions since 2023, with more than a dozen launches and reentries planned through 2028. Proceeds will increase flight cadence and deepen pharmaceutical partnerships toward the first medicine manufactured in space. (Link)
  3. B Capital has led a $33 million Series B in Austin-based microbiome testing company Tiny Health, joined by Spero Ventures, The Venture City, Overwater Ventures, Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels and Pari Passu Ventures. B Capital led Tiny Health’s oversubscribed $33 million Series B, bringing total funding to $46 million. Existing backers Spero Ventures, The Venture City and Overwater Ventures participated alongside new investors Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels and Pari Passu Ventures. B Capital manages more than $12 billion and takes a board seat through Senior Principal Nick Whitehead. Proceeds fund clinical research, practitioner education, the Powered by Tiny B2B platform and TinyAI, trained on nearly 200,000 microbiome profiles. Tiny Health also committed $5 million to a Microbiome Research Program. (Link)
  4. Canvas Ventures has led an oversubscribed $10 million Series A in San Francisco-based healthcare AI company Parakeet Health, with Blank Space Ventures, StoryHouse Ventures and HMC INQ participating. Canvas Ventures led Parakeet Health’s oversubscribed $10 million Series A, taking total funding to $13 million. The raise follows 10x annual recurring revenue growth over the past year. Parakeet’s platform manages inbound calls, proactive outreach, fax processing and web scheduling, and now serves six of the ten largest U.S. dermatology groups, supporting more than 2,800 providers across 1,100-plus locations. Canvas co-founder Rebecca Lynn cited the team’s ability to win major healthcare customers and deliver measurable ROI. Parakeet charges on a performance basis tied to verified results. Link (Link)
  5. Biotia has raised an oversubscribed $9 million financing from Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels and Red Bear Ventures, alongside VillageMD co-founders Tim Barry and Clive Fields. New York clinical metagenomics company Biotia closed an oversubscribed $9 million round that exceeds its previously announced Series A. Investors include Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels and Red Bear Ventures, plus VillageMD co-founders Tim Barry and Clive Fields. DigitalDx Ventures CEO Michele Colucci becomes board chair and Barry joins the board. Capital will scale Biotia’s New York laboratory, launch further women’s health diagnostics and expand into orthopedics. Its BIOTIA-ID urine test reports 97% sensitivity and 99% specificity. (Link)
  6. Cobalt Capital has led an undisclosed Series A in Los Angeles-based predictive movement health company p°Motion, joined by WME Group, Nimble Ventures, Canaan Ventures and Soul Ventures. Cobalt Capital led the Series A financing, building on support from a broader investor group including WME Group, Nimble Ventures, Canaan Ventures, Soul Ventures and strategic investors connected to professional sports, technology and institutional capital. Neither round size nor valuation was disclosed. Founded in 2019, p°Motion applies machine learning to an assessment methodology built on more than 40 years of movement research, and says it can identify certain injury risks up to 18 months before they occur — a company-reported claim without published validation data. Proceeds fund AI and engineering hiring plus commercial expansion into healthcare. (Link)
  7. Advent has led, and Temasek co-led, a $555 million Series G in Medicare Advantage insurer Devoted Health as part of a $1.18 billion financing. Devoted Health closed $555 million of Series G primary funding within a $1.18 billion primary and secondary financing. Advent led with Temasek as co-lead, joined by The Space Between — both independently and alongside Centricus — plus GIC, Franklin Templeton, Generation, VZVC, Emerson Collective, Premji Invest and Andreessen Horowitz. The same investors committed $622 million for a shareholder tender offer expected to close later in the fourth quarter. Membership has grown from 212,000 in December 2025 to 538,000 by September 2026, and Devoted is entering 342 new counties and five new states. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update September 28th, 2026

LECO_Weekly-Healthcare-News_9-28-2026Download

Healthcare Weekly News and Deals – Sept 28th, 2026

  1. Webster Equity Partners to acquire Lifecore Biomedical (NASD: LFCR) for $6.28 per share in cash plus CVRs, valuing the sterile-injectable CDMO at up to $663.7 million. Lifecore is a Chaska, Minnesota contract manufacturer for sterile injectables — syringes, vials and cartridges, including complex formulations — and a large producer of injectable-grade hyaluronic acid. Common holders get $6.28 a share in cash, a 49.5 percent premium to the September 25 close. Contingent value rights tied to 2028 and 2029 revenue and 2030 EBITDA can add $160 million in the aggregate, or $9.67 a share if every milestone hits. MidCap Financial, MSD Partners and Alcon committed the debt; Webster committed the equity. The merger agreement includes a 30-day go-shop. The company stays in Chaska under the Lifecore name, with a close aimed at year-end. (Link)
  2. Ardan Equity is investing in clinical trial technology company Clinical ink alongside existing backer GI Partners at a total enterprise value of more than $500 million. Healthcare software specialist Ardan Equity is investing in Clinical ink, the clinical trial technology company, alongside existing backer GI Partners. GI Partners acquired a majority interest in Clinical ink in August 2020, when prior investor NovaQuest stayed on as a minority holder and management invested significantly. The new round adds a sponsor that invests exclusively in healthcare software, while GI Partners keeps its exposure as Clinical ink builds on a platform that brings data, technology and patient science together for trial sponsors. (Link)
  3. Clearlake Capital Group and Charlesbank Capital Partners have agreed to inject approximately $175 million of preferred equity into distressed healthcare software provider Symplr, as part of a creditor-backed recapitalization designed to shore up its finances and extend its debt maturities. Clearlake Capital Group and Charlesbank Capital Partners will provide around $175 million of preferred equity to Symplr under a restructuring agreed with several creditor groups, with the sponsors deferring interest on newly issued junior debt to preserve cash. Second-lien lenders are expected to add $103.5 million through a first-out second-lien loan, while first-lien holders would receive a 100-basis-point coupon increase for extending the 2027 maturity by three years. Symplr’s roughly $1.2 billion first-lien term loan was recently quoted near 71.4 cents on the dollar amid concerns over AI’s impact on software. Company is held in a single-asset continuation vehicle. (Link)
  4. Existing shareholders Star One Global Capital Limited and Eliyahou Harari have fully funded an $18 million registered direct offering in Nasdaq-listed capsule endoscopy developer CapsoVision (CV), buying 3,163,444 shares at $5.69 each. CapsoVision (CV) has raised about $18 million through a registered direct offering funded entirely by existing shareholders Star One Global Capital Limited and Eliyahou Harari. Under a September 17 securities purchase agreement, the investors agreed to buy 3,163,444 shares at $5.69, a roughly 5% discount to the prior Nasdaq close, with no underwriter involved. The insider-backed raise, approved by the board and reviewed by the audit committee, strengthens the balance sheet of the Saratoga, California-based capsule endoscopy developer, which has a market value of about $299.8 million. Proceeds will fund sales and marketing, R&D and working capital as it advances AI-assisted CapsoCam Plus and a second-generation colon capsule. (Link)
  5. Lexeo Therapeutics (NASD: LXEO) has agreed to acquire Mantle Therapeutics for $8.3 million in cash and equity plus up to $13 million in milestones, adding Friedreich ataxia programs. Mantle is a private clinical-stage company with four Friedreich ataxia candidates designed to raise or replace frataxin in the brain. One is an oral combination already in patients; another is an RNA construct linked to an anti-TfR1 antibody fragment. On the same day Lexeo signed a sponsored-research agreement with Weill Cornell on intra-cisternal dosing of LX2006 and took options from Vivet Therapeutics and Apertura Gene Therapy. Management says the cash on hand still lasts into 2028. The acquisition is expected to close this quarter. (Link)
  6. Avesi Partners has made an investment in St. Louis-based New Age Medical, a spinal MedTech hub connecting manufacturers, sales reps, hospitals and surgeons. Avesi invests in lower-middle-market healthcare services and technology and now has more than $2.2 billion under management. New Age sits between implant makers and the operating room: more than 85 OEMs, 100-plus independent reps, 200-plus hospitals and surgery centers, and 350-plus spine surgeons. Founder and chief executive Kevin Bly remains in place with the current management team. The check is meant to move product from the plant to the table faster, not to recapitalize a clinic chain. (Link)
  7. GoodVets has acquired WellHaven Pet Health, adding more than 40 veterinary hospitals and taking the combined network from 75 to 116 locations. GoodVets, based in Chicago, has mostly opened hospitals from scratch with local veterinarians. WellHaven already runs more than 40 clinics across seven states, with clusters in the Pacific Northwest and the Midwest. Those sites will move onto GoodVets’ central operating model and, over time, onto the GoodVets name. Existing clinic teams and patient panels stay in place. Terms were not published. (Link)
  8. Prisma Health has agreed to acquire 36 South Carolina urgent care centers, formerly Doctor’s Care, from Novant Health. Novant had been running the former Doctor’s Care sites. Closing is set for November 1, when the clinics convert to the Prisma Health Urgent Care name and about 500 employees come across. Patients keep walk-in, booked and virtual visits — including respiratory tests, X-ray and labs — and gain a referral path into Prisma’s hospitals and specialists. Most locations stay put; a few may fold into a neighboring center, with affected staff offered jobs nearby. Purchase price was not disclosed. (Link)
  9. Forge, the B2B events and media company backed by Apollo Funds (APO), has agreed to acquire Becker’s Healthcare from Pamlico Capital, combining it with Fierce Healthcare and Life Sciences to create a scaled healthcare and life sciences media and events platform. Forge, formed by combining Emerald and Questex after their acquisition by Apollo Funds (APO) in July 2026, has signed a definitive agreement to acquire Chicago-based Becker’s Healthcare from Pamlico Capital. The deal includes Becker’s 16 annual conferences, more than a dozen digital publications and its newsletters, podcasts and executive communities, which reach over 1.5 million healthcare leaders. Combined with Forge’s Fierce Healthcare and Life Sciences, the platform will run more than 35 live events. (Link)
  10. May River Capital has sold Addison, Illinois-based environmental monitoring platform Dickson to Copeland, a portfolio company of Blackstone (BX), expanding Copeland’s cold chain monitoring capabilities for healthcare and life sciences customers. May River Capital has sold Dickson to Copeland, a Blackstone (BX) portfolio company with approximately 18,000 employees across more than 40 countries. May River acquired Dickson in April 2018 and turned the family-owned, single-site business into a global environmental monitoring platform serving customers in more than 50 countries from Illinois, France and Malaysia. During its ownership, May River invested in next-generation sensing and cloud-based monitoring and took private Oceasoft, a publicly traded French monitoring company. Dickson serves regulated life sciences, pharmaceutical, healthcare and medical device customers, advancing Copeland’s cold chain intelligence offering (Link)
  11. Arcventis Health Partners has made a majority growth investment in Chicago-based functional medicine and hormone health provider Aligned Modern Health, with existing investor Harbour Point Capital remaining a meaningful shareholder, to fund national telehealth expansion and the launch of peptide therapy. Arcventis Health Partners, a US healthcare investor with growth equity and growth buyout strategies, has taken a majority stake in Aligned Modern Health, while Harbour Point Capital stays on as a meaningful investor. AMH operates 15 clinics across Chicago, a telehealth practice serving patients in more than 20 states and a team of 100-plus clinicians spanning functional medicine, hormone replacement therapy, chiropractic care and acupuncture. The capital will fund national expansion, broader clinical offerings including newly launched peptide therapy, the digital patient experience and provider hiring. AMH accepts most major insurance, which sets it apart from self-pay and concierge models. No valuation was disclosed. (Link)
  12. 1315 Capital has led a growth capital investment in Richmond, Texas-based medical device developer and manufacturer Velentium Medical, joining existing investor Great Point Partners as a significant shareholder to scale commercial manufacturing of wearable and implantable devices. Philadelphia-based 1315 Capital, which manages over $1 billion, led a growth capital investment in Velentium Medical, a developer and manufacturer of active Class II wearable and Class III implantable medical devices. Great Point Partners, which manages about $1.7 billion, remains a significant shareholder. Velentium operates from a 50,000-square-foot manufacturing facility after expanding from an engineering shop into commercial production. Proceeds go to manufacturing capacity, product development and regulatory infrastructure. 1315 takes minority and majority stakes in commercial-stage healthcare and outsourced medtech companies. (Link)
  13. Newly launched Boston private equity firm Haelan Capital Partners has made its first investment in Boca Raton, Florida-based virtual acute care provider NuView Health, pairing its capital with an in-house team of experienced healthcare operators. Boston-based Haelan Capital Partners launched with an investment in NuView Health, a hybrid onsite and virtual care partner to hospitals and provider groups across ICU, neurology, stroke and infectious disease. Founded by Gregg Osenkowski and Scott Castle, Haelan pursues control buyouts of founder-owned, lower middle market tech-enabled healthcare services businesses. Its Growth Enablement Model places an in-house C-suite of healthcare operators alongside the investment team to build portfolio infrastructure. NuView has about 150 active providers across more than 60 facilities and a 15-year clinical track record, and its doctors have treated over one million US patients. No deal value was announced. (Link) (Link)
  14. 5th Century Partners has completed a strategic investment in ION PT Network, a founder-led physical therapy management company serving the workers’ compensation market, to refine its commercial strategy while preserving its clinician-led model. Chicago-based 5th Century Partners, which invests in lower middle-market healthcare and business services companies, has made a strategic investment in ION PT Network. Founded in 2017 by physical therapist Joseph Noel, ION manages workers’ compensation physical therapy for payers, employers and third-party administrators through independent providers, assigning each referral to a licensed clinical case owner; more than half its staff are licensed therapists. 5CP plans to refine ION’s business and commercial strategy while preserving its clinical model. Noel remains CEO, supported by newly added chief revenue officer Sara Mulick and chief financial officer Alina Schreiber. Terms were not disclosed. (Link)
  15. Ascend Learning has acquired AI-powered healthcare workforce scheduling platform M7 Health, combining it with its StaffGarden and Laudio brands to support clinicians from schooling through day-to-day staffing. Boston-based Ascend Learning, a healthcare and learning technology company, has acquired M7 Health, whose AI platform forecasts staffing demand, balances schedules and recruits to fill gaps for health systems ranging from academic medical centers to rural hospitals. M7 customers have cut administrative burden by more than 60%, premium labor spend by 35% and nurse turnover by 30%. The deal pairs M7 with Ascend’s StaffGarden and Laudio brands, extending a platform that supports more than 60% of nursing schools and 245,000 allied health professionals a year. It follows Ascend’s August acquisition of TAMS, continuing its expansion in healthcare workforce technology. Terms were not disclosed. (Link)
  16. Carisk Partners has acquired onsite occupational healthcare provider FirstCare Onsite to connect injured workers with care from the point of injury through complex recovery in the workers’ compensation market. Tampa-based Carisk Partners, a specialty risk transfer, care coordination and clinical services company in workers’ compensation, has acquired FirstCare Onsite. FirstCare places clinicians at employer worksites and has historically resolved roughly 30% of workplace injuries before they became claims. Carisk will keep FirstCare’s onsite model while routing complex cases into its specialty care, complex care management and behavioral health services. Carisk plans to invest in expanding FirstCare’s onsite programs, particularly among large employers with concentrated workforces. (Link)
  17. MGA Homecare has acquired Care IV Home Health’s private duty nursing division, entering Arkansas as its seventh state and expanding in-home care for medically complex pediatric and adult patients. MGA Homecare has acquired Care IV Home Health’s private duty nursing division, which has served medically complex Arkansas patients for more than three decades, including children and adults who depend on ventilators or tracheostomies. The carve-out let’s Care IV focus exclusively on its Medicare intermittent skilled home health business. MGA is keeping the division’s leadership, headed by Joseph Kennon, and its nursing workforce, and plans to use the unit to reach rural and underserved patients and pursue value-based partnerships with health plans. MGA now has more than 5,500 team members serving over 6,000 patients daily across seven states. Terms were not disclosed. (Link)
  18. Nashville-based Chord Specialty Dental Partners has entered Ohio by partnering with Ohio-based pediatric practices Prairie Kids Dental of West Jefferson and Clover Kids Dental of Columbus, extending its network to eight states. Chord Specialty Dental Partners, a Nashville-based dental support organization, has partnered with two Ohio pediatric practices: Prairie Kids Dental in West Jefferson and Clover Kids Dental in Columbus. Both practices are led by founder Kimberly Gill, DDS. The deal marks Chord’s entry into Ohio and brings its footprint to eight states. Chord supports more than 60 partner practices across pediatric dentistry, orthodontics, oral surgery and ambulatory surgery centers. The deal adds to an active consolidation market: professional services, the segment Healthcare DealHub files it under, leads that site’s 2026 year-to-date healthcare deal count with 386 transactions. Terms were not disclosed. (Link)
  19. Hope Network has acquired Developmental Enhancement Behavioral Health, a roughly 90-person West Michigan autism services provider, nearly doubling the footprint of its Center for Autism. Michigan’s Hope Network has acquired Developmental Enhancement Behavioral Health, a roughly 90-person provider of Applied Behavior Analysis, psychological assessment and counseling with locations in Grand Rapids, Holland and Georgetown Township. The deal nearly doubles the footprint of Hope Network’s Center for Autism, which operates in Kentwood, Holland Township, Livonia and Okemos. Financial terms were not released. Integration is planned in phases through about spring 2027. DE locations, clinicians and care models stay in place, with no immediate rebranding. (Link)
  20. Penn Medicine, Independence Blue Cross (IBX) and Regent Surgical have formed a new joint company to develop at least 18 ambulatory surgery centers across Greater Philadelphia, combining health-system, payer and ASC operator capabilities to shift procedures into lower-cost outpatient settings. Penn Medicine, Independence Blue Cross and Regent Surgical are launching a new company to develop at least 18 ambulatory surgery centers across Pennsylvania, New Jersey and Delaware. Penn brings the clinical network, IBX the payer, and Regent the ASC development and operating platform. Hospital facility fees can run close to twice ASC fees; Vizient has projected outpatient surgical volumes up 20 percent through 2035. No financial terms were disclosed. (Link)
  21. OceanSound Partners-backed PAR Excellence Systems, based in Cincinnati, Ohio, has acquired Madison, Wisconsin-based healthcare RFID inventory tracking company Terso Solutions from Promega Corporation to build a unified hospital inventory management platform. PAR Excellence Systems, an OceanSound Partners portfolio company, has acquired Terso Solutions from its parent, Promega Corporation. Terso makes ultra-high-frequency RFID enclosures, open-air readers and cloud software that let hospitals track high-value inventory in real time, with thousands of enclosures installed across hundreds of hospitals and health systems, including the US Department of Veterans Affairs. The companies have worked together for years, and hundreds of PAR clients already connect Terso enclosures to PAR’s TrackCore tissue and implant tracking software. The combined business serves about 1,700 hospitals, nearly 30% of the roughly 6,000 in the US, and aims to replace fragmented point solutions. Financial terms were not disclosed. (Link)
  22. RS2 Healthcare Partners has completed its first new platform investment since refocusing exclusively on healthcare, backing Hatboro, Pennsylvania-based medical device contract manufacturer KMM Group and appointing J. Mark King as CEO. Boston-based RS2 Healthcare Partners, formerly Riverside Partners, has invested in KMM Group, a vertically integrated precision contract manufacturer of complex, tight-tolerance components for the medical device industry. The deal is RS2’s first new platform since the firm rebranded earlier this year to focus exclusively on lower middle-market healthcare; RS2 has raised $1.6 billion in total commitments since its 1989 founding. RS2 appointed J. Mark King, previously CEO of former RS2 portfolio company Tegra Medical, as KMM’s president and CEO. Founders John Shegda and Eric Wilhelm stay on as chief technology officer and executive vice president of business transformation, respectively. No terms were announced. (Link)
  23. Arlington Capital Partners portfolio company AVS Bio has acquired Cambridge, UK-based bio-reagent supplier Biorbyt Ltd. to expand its biomaterials catalog and ecommerce capabilities. AVS Bio, a Norwich, Connecticut provider of bioprocessing inputs and services backed by Arlington Capital Partners, has acquired Biorbyt Ltd., a Cambridge, UK supplier with more than 1 million SKUs of antibodies, proteins, ELISA kits and molecular biology reagents. The add-on expands AVS Bio’s research catalog and adds Biorbyt’s ecommerce channel. Arlington is investing from its $6 billion Fund VII. Biorbyt’s leadership team stays in place. (Link)
  24. Audax Private Equity-backed Elevate ENT Partners has acquired West Texas Ear, Nose & Throat, expanding its otolaryngology physician practice management platform across Texas. Elevate ENT Partners, backed by Audax Private Equity, has acquired West Texas Ear, Nose & Throat, which operates locations in Abilene and Brownwood. The practice is led by its sole physician, Dr. Jason Acevedo, with 11 healthcare and administrative staff, and provides otolaryngology, head and neck surgery and allergy treatment. The deal is Elevate’s first practice acquisition of 2026 and extends its reach across Texas. Elevate supports a national network of more than 80 otolaryngology centers and over 130 affiliated physicians. It gives physician-led ENT and allergy practices management infrastructure, revenue cycle management, payer contracting, human resources and operational scale. Financial terms were not disclosed. (Link)
  25. Rays of Belief Limited (MOMSBELIEF), operating as Mom’s Belief, has acquired 100% of New York-based pediatric Early Intervention provider City Pro Group through its subsidiary Mom’s Belief US Inc. to build a US developmental care platform. India-based Rays of Belief (MOMSBELIEF), which runs 136 developmental care centres under the Mom’s Belief brand, has acquired all of City Pro Group through wholly owned subsidiary Mom’s Belief US Inc., effective September 18, 2026. Founded in 1995, CPG provides pediatric Early Intervention and special education services across the Bronx, Brooklyn, Manhattan and Long Island. CPG generated US$11.43 million (about ₹97.27 crore) of FY25 revenue, more than the acquirer’s FY26 consolidated revenue of ₹81.66 crore, so the deal could roughly double the group’s scale. The acquisition gives the company a US operating platform and a two-way exchange of clinical know-how between India and the US. Consideration was not disclosed. (Link)

Venture Deals and Other

  1. Pershing Square Inc. (PS), the Ackman Oxman Institute and an undisclosed life sciences investment fund have co-led Precision Neuroscience’s oversubscribed $250 million Series D, joined by Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners (parent Korea Investment Holdings, KRX: 071050), Hitachi Ventures (parent Hitachi, TYO: 6501) and JSL Health Capital, to advance its brain-computer interface toward commercialization. Pershing Square Inc. (PS), the Ackman Oxman Institute and an undisclosed life sciences fund co-led Precision Neuroscience’s oversubscribed $250 million Series D, lifting total capital raised to $430 million since the brain-computer interface developer was founded in 2021. Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners (parent KRX: 071050), Hitachi Ventures (parent TYO: 6501) and JSL Health Capital also joined, spanning sovereign wealth, venture, public-market and family-office capital. Precision holds FDA clearance for its Layer 7 cortical interface, has completed more than 100 procedures across 18 institutions and partners with Medtronic (MDT). Proceeds will fund clinical expansion, further FDA review and commercialization. (Link)
  2. Francisco Partners has led a $155 million Series E in pharmacy benefit management and care navigation company Rightway, with participation from existing investors Thrive Capital and Khosla Ventures, to expand its AI and technology capabilities. Francisco Partners led a $155 million Series E in New York-based Rightway, with existing investors Thrive Capital and Khosla Ventures participating. Rightway provides pharmacy benefit management and care navigation for employers. Its financial model removes any incentive to profit from higher drug spend, and pharmacists guide members to the most appropriate medications at the lowest cost. It now counts 45 Fortune 500 companies as clients, nearly 10% of the index. Its SureSpend model caps total pharmacy spend and covers GLP-1s and rare high-cost drugs at net cost with 100% rebate pass-through. Proceeds will expand Rightway’s AI and technology. Francisco Partners, with over $75 billion raised, brings healthcare technology expertise. (Link)
  3. .406 Ventures has led a $22 million Series A in at-home cervical cancer screening company Teal Health, with continued backing from Emerson Collective (managed by Yosemite), Forerunner and Serena Ventures and new participation from Japan-based MPower Partners, ahead of broad insurance coverage in 2027. .406 Ventures led a $22 million Series A in Teal Health, maker of the Teal Wand, the first FDA-authorized self-collection device for at-home HPV cervical cancer screening. Emerson Collective (managed by Yosemite), Forerunner and Serena Ventures returned, and Japan-based MPower Partners joined, lifting total funding to $45 million. Federal guidelines due in January 2027 require most health plans to cover self-collection screening. Proceeds go to payor, health system, employer and provider contracts, direct-purchase channels and hiring. Teal reports that 59 percent of women who use the wand had been underscreened. (Link)
  4. NEA has led a $20 million Series A in Nashville-based AI post-acute admissions platform Basalt Health, with participation from existing investors Frist Cressey Ventures and 25m Health, to scale across Lifepoint Health and ScionHealth hospitals. Return investor NEA led a $20 million Series A in Nashville-based Basalt Health, with existing backers Frist Cressey Ventures and 25m Health, 25madison’s healthtech venture studio, participating; total funding now stands at about $24.5 million. Basalt’s AI reads post-acute referrals and checks them against clinical and payer rules, cutting median processing time by 86% at Lifepoint Health. The capital will support scaling across 111 markets by the end of 2026, including 62 ScionHealth hospitals and 49 Lifepoint markets, plus expansion into discharge and payer workflows. NEA, with more than $38 billion in assets under management, and Frist Cressey, with $846 million, bring deep healthcare networks. (Link)
  5. Accel has led a $10 million seed round in New York-based healthcare conversational AI company Clarion Health, with participation from Y Combinator, to automate scheduling, referrals, prescription refills and patient communications for providers. Accel led a $10 million seed round in New York-based Clarion Health, with participation from Y Combinator. Clarion’s conversational AI platform automates scheduling, referrals, prescription refills and patient communications for healthcare providers. Founded in 2024 by Ryan Gallagher and Jeffrey Lamothe, the company is building what Y Combinator calls an AI communication layer for healthcare, with agents that handle the overwhelming volume of calls and messages providers receive. The Accel-led round gives the two-year-old startup capital to scale its AI communication infrastructure for healthcare providers, and the company is actively hiring following the raise. (Link)
  6. Surgeon investors have backed Redefine Surgery’s oversubscribed pre-seed round, bringing total capital raised to $10 million, as Catalyst OrthoScience joins as Founding Partner to co-develop surgical intelligence for shoulder replacement. Redefine Surgery has closed an oversubscribed pre-seed round backed mostly by surgeon investors, bringing total capital raised to $10 million. The company is combining computer vision, software and robotics in a portable platform for the operating room, starting in orthopedics. Naples, Florida-based Catalyst OrthoScience joined as founding partner on surgical intelligence for shoulder replacement. More than 25 surgeons advise the company. Commercial use still requires regulatory clearance. (Link)
  7. Ground State Ventures has led a $3.4 million pre-seed round in Azulene Labs, with participation from existing investor Entrada Ventures and angel investors, to build physics-based AI models for drug and materials simulation. Ground State Ventures led a $3.4 million pre-seed round in Azulene Labs, with participation from existing investor Entrada Ventures and angel investors. Azulene builds physics-based models trained on quantum-mechanical data for drug and materials simulation. Co-founder Nicolas Sawaya previously led quantum chemistry algorithm work at Intel Labs. Proceeds go to hiring and to work with biotech and industrial chemistry customers. (Link)
  8. Elmstead Partners, Chisos Capital, the Chemical Angel Network and individual angel investors have backed Axio BioPharma’s $2.4 million pre-seed round to connect biomanufacturing data between pharma companies and their manufacturing partners. Elmstead Partners, Chisos Capital, the Chemical Angel Network and a group of individual angels invested in Axio BioPharma’s $2.4 million pre-seed round. The Madison, Wisconsin company connects manufacturing data between drug sponsors and their manufacturing partners through a product called Lattice, with each side keeping its own systems. Proceeds fund first deployments with design partners and further work on Rosetta, an ontology layer that maps those systems to each other. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update September 21st, 2026

LECO_Weekly-Healthcare-News_9-21-2026Download

Healthcare Weekly News and Deals –Sept 21st, 2026

  1. CareTrust REIT (NYSE: CTRE) Acquires Southwest Skilled-Nursing Portfolio for $400 Million First public print of a transaction effective September 1. The book is 2,622 licensed SNF beds, triple-net to the incumbent operator with inflation escalators and renewal options. Structured as a joint venture; CareTrust put in about $380 million from cash and settled equity forwards and models an 8.6% stabilized yield. Sourced off-market in markets where both landlord and operator already have scale. Year-to-date deployment is now about $1.9 billion and Q3-to-date about $710 million. Management reloaded the near-term pipeline at about $600 million. (Link)
  2. Lisata Therapeutics (NASD: LSTA) Acquires Marea Therapeutics; $225 Million PIPE Concurrent Stock-for-stock reverse merger plus PIPE. RA Capital, Forbion, Third Rock, Alpha Wave, Perceptive, Sofinnova, Omega, Surveyor/Citadel, Columbia Threadneedle, Nantahala, Affinity, venBio and Rock Springs filled the round. Combined cap table: legacy Lisata about 2.4%, Marea holders about 59.5%, PIPE about 38.1%. Assets are MAR001/005, an ANGPTL4 monoclonal in Phase 2b for severe hypertriglyceridemia, and MAR002, a growth-hormone-receptor antagonist headed to Phase 2 in acromegaly. Runway into 2028; key reads targeted for the fourth quarter of 2027. (Link)
  3. Veracyte (NASD: VCYT) acquires Convergent Genomics for $150 million in cash plus up to $30 million in milestone payments, adding urine-based bladder cancer testing. Veracyte closed its purchase of Convergent Genomics on September 14. It paid $150 million in cash at closing, subject to customary adjustments, with up to $30 million more tied to UroAmp publication and reimbursement milestones. Convergent was founded in 2015 in partnership with Oregon Health & Science University and runs a CLIA-certified lab in South San Francisco. Its UroAmp urinary tumor DNA assay is validated for monitoring therapy response and post-treatment surveillance in non-muscle-invasive bladder cancer. The asset sits alongside Decipher Bladder and TrueMRD, so Veracyte now covers urine, tissue and blood across the bladder cancer pathway. Management expects no material impact on 2026 EBITDA guidance. (Link)
  4. Oaktree commits up to $115 million in milestone-based capital to Saol Therapeutics ahead of the FDA decision date for SL1009. Funds managed by Oaktree will provide up to $115 million to Saol Therapeutics, a private clinical-stage drug company in Roswell, Georgia. An initial tranche funds launch preparation, and the rest is released as regulatory, clinical and commercial milestones are met. The lead drug, SL1009 (sodium dichloroacetate), treats pyruvate dehydrogenase complex deficiency, a rare mitochondrial disease with no approved therapy. The FDA rejected an earlier application in 2025. Saol resubmitted, and the FDA’s decision date is December 30, 2026. Later tranches would fund SL1009 in congenital lactic acidosis and expand SL1002 into more pain indications and spasticity. (Link)
  5. Agora makes a $47 million first investment in Vheda Health, a Columbia, Maryland outcomes and analytics platform for health plans. Agora is a San Francisco private equity firm focused on healthcare technology, founded by Neil Vangala. It has invested $47 million in Vheda Health. This is Agora’s first deal and the first institutional capital in Vheda’s 13-year history. The previously bootstrapped company runs chronic-condition and maternity programs for high-risk Medicaid, Medicare and Special Needs Plan members. It cites more than $975 million in savings for health plan partners and an average 3:1 return on investment. Co-founder and CEO Shameet Luhar stays. The money funds expansion beyond 18 states, new analytics products and targeted acquisitions. (Link)
  6. Ambu (Nasdaq Copenhagen: AMBU B) acquires U.S.-based TIMS Medical (Foresight Imaging) for $45 million upfront plus up to $20 million in milestones to advance its EndoIntelligence platform. Ambu, the Danish single-use endoscopy leader, has bought Foresight Imaging, LLC, which trades as TIMS Medical. It is paying $45 million upfront and up to $20 million in milestones, for total consideration of as much as $65 million. Founded in 2004, TIMS builds hardware and software that record procedure imaging and integrate it into hospital EMR and imaging systems. Its flagship TIMS MVP is widely used in ENT procedures, including FEES exams. The business has about 55 employees, roughly $15 million in annual revenue and around 7,000 installations across U.S. hospitals. Ambu expects the deal to accelerate revenue growth and kept its FY2025/26 outlook unchanged. (Link)
  7. WJRJJ Ventures, owned by Copart (NASD: CPRT) founder Willis Johnson, completes a $40 million private placement in HealthStream (NASD: HSTM). WJRJJ Ventures bought 1.5 million HealthStream shares at $29.50 each. That comprised 1,355,932 new shares for about $40 million and 144,068 existing shares bought from CEO Robert Frist Jr. for about $4.25 million. Frist remains the largest shareholder, with about 16.4%. Johnson, a Nashville-area entrepreneur, was also the first investor in Empath Nursing, founded in 2025. HealthStream sells workforce technology to hospitals and will use the money for product investment and possible acquisitions. (Link)
  8. Arsenal Capital Partners–backed Endpoint Clinical acquires Boston-based Bluefin, a clinical supply forecasting and planning technology provider. Endpoint Clinical, the randomization and trial supply management vendor Arsenal acquired in 2024, has bought Bluefin, a Boston cloud platform for planning clinical supply demand and distribution. The add-on moves Endpoint upstream from RTSM execution into forecasting. Supply plans will link to live enrollment and inventory data, so sponsors can anticipate shifts rather than react to them. Bluefin will keep operating independently and will still connect to competitors’ RTSM systems. Endpoint will add implementation, quality, project management and customer support. Bluefin CEO Andy Maltun stays. (Link)
  9. Seven Hills Capital–backed Spa Medicca of Canton, Ohio acquires Dr. Nicholas E. Sherock LLC & Associates, an Ohio women’s health practice in Massillon and Orrville. Spa Medicca has acquired Dr. Sherock & Associates, a two-location women’s health group in Massillon and Orrville. Dr. Nicholas Sherock leads a five-person clinical team offering gynecologic care, hormone replacement therapy, minimally invasive surgery and aesthetic services. Those services map onto Spa Medicca’s focus on medical aesthetics, hormone optimization and women’s health. The deal adds density in northeast Ohio after earlier work such as Amy Brenner, MD & Associates in Cincinnati. Patients keep existing providers and locations. (Link)
  10. Gauge Capital–backed Reliable Medical acquires Freedom in Mobility and Action Seating & Mobility, expanding CRT coverage across Alabama, Tennessee, Oklahoma, Arkansas and Colorado. Reliable Medical is a Nashville CRT and home medical equipment provider Gauge recapitalized from Seven Hills in January. Freedom in Mobility adds three sites in north Alabama and Tennessee; president Teresa Glass Owens and COO Forrest Owens join. Action Seating & Mobility adds Tulsa, Oklahoma City, Muskogee, Fayetteville, Sherwood and Denver — manual and power chairs, custom seating, ATP-led fitting and repair. Combined network is more than 50 locations. Two add-ons in one week on the same platform. (Link)
  11. NMS Capital launches Asurgence Medical by recapitalizing ENDOCORP and acquiring Medical Optics from Probo Medical. NMS partnered with management to recapitalize Endoscopy Corporation of America of Southfield, Michigan and at the same time bought Medical Optics of Tamarac, Florida from Probo Medical. ENDOCORP supplies more than 15,000 repair-part SKUs for flexible endoscopes. Medical Optics repairs and resells flexible and rigid scopes across manufacturers. Both keep their names as Asurgence subsidiaries. Former Probo CEO Michael Asmer becomes CEO. Thesis is aging equipment fleets and hospital pressure to avoid OEM overhaul pricing. (Link)
  12. Amulet Capital Partners closes a continuation vehicle to recapitalize US Fertility. New and existing investors participated. US Fertility was formed in 2020 and now supports more than 120 clinic and IVF lab locations and over 200 physicians. It has treated more than 400,000 patients. The deal builds on L Catterton’s 2025 entry as co-lead alongside Amulet and the physician partners. Amulet, a healthcare-only sponsor managing about $3.8 billion, stays involved. The new capital funds geographic expansion and clinical innovation. (Link)
  13. Sheridan Capital Partners acquires a majority stake in PtEverywhere, a Raleigh-based practice management and payments platform for physical therapy clinics. Sheridan completed a majority investment in PtEverywhere. The Raleigh platform brings scheduling, clinical documentation, billing and collections into one workflow for small and mid-sized outpatient physical therapy clinics, including cash-pay and hybrid reimbursement models. CEO Andrew Shofner stays. Sheridan plans organic growth and add-ons that broaden the product into adjacent rehab segments. The deal sits next to Sheridan’s 2025 investment in post-acute billing vendor National Care Systems. (Link)
  14. Martis Capital– and Din Ventures–backed Archway Dental Partners acquires Veale Dental, its first Massachusetts practice. Archway Dental Partners, based in Danbury, Connecticut, acquired Veale Dental, a two-location general practice in South Easton and Dartmouth. This is Archway’s first Massachusetts practice and its third acquisition of 2026, after five deals in 2025. The group began as the four-location Dental Associates of Connecticut and now supports more than 40 practices across Connecticut and New York. Entry into a new state rather than an add-on in an existing market. (Link)
  15. Neuberger and KKR (NYSE: KKR) agree to acquire a significant minority stake in Datavant, which remains controlled by New Mountain Capital. Funds managed by Neuberger Capital Solutions and Neuberger Private Markets, together with KKR’s Strategic Investments Group, agreed to buy a significant minority stake in Datavant. New Mountain Capital, an investor since 2014, keeps control. Datavant’s network spans more than 80,000 providers and 75 of the top 100 health systems, and its data touches about 90% of the U.S. population. Growth capital into a scaled asset rather than an exit, funding further digitization and clinical AI. Closing expected in the fourth quarter of 2026. (Link)
  16. Parthenon Capital–backed MRO acquires Vyne Medical from TJC-owned Vyne, adding clinical data intake and document processing. MRO, a Norristown clinical data management platform, acquired Vyne Medical from Vyne, a TJC portfolio company. Vyne Medical turns paper, fax, voice and image inputs into structured data for more than 800 hospitals. Together the companies serve over 2,500 hospitals and 35,000 clinics. Intake tools feed MRO’s medical-records release and data exchange services. Vyne Dental is not part of the deal and stays with TJC. Clean sponsor-to-sponsor handoff. (Link)
  17. NewSpring-, Kineticos-, HealthQuest- and Great Point–backed Kincell Bio Merges with Cellipont to Form Kincellis Advanced Therapies U.S. cell-therapy CDMO combination. Kincell’s immune-cell shop plus Cellipont’s stem, iPSC, MSC, dendritic, exosome and mRNA work. About 140,000 square feet across Gainesville, Research Triangle Park and The Woodlands; 16 qualified GMP suites; more than 150 GMP batches released; 10 INDs this year; 200-plus staff. Darren Head is CEO. Equity led by NewSpring with Kineticos Life Sciences, HealthQuest Capital and Great Point Partners; debt from J.P. Morgan. (Link)
  18. Arlington-Backed Everest Clinical Research Acquires Firma Clinical’s Data Services Unit Toronto data-first CRO buying Firma DS, a biometrics and clinical-data book that has touched more than 1,000 studies and 60-plus NDAs across oncology, neurology, rare disease, hepatology and nephrology. Adds delivery capacity in the U.S. and Asia-Pacific. Firma DS clients get Everest’s full-service stack — regulatory, operations, safety, medical writing — on one CRO. Arlington Capital has owned Everest since 2020. (Link)
  19. Gauge-Backed Rovia Clinical Research Acquires Pinnacle Research Group and Cullman Clinical Trials in Alabama Site-network add-ons on Gauge’s Rovia platform. Pinnacle is an Anniston-area multi-specialty site founded in 1998, with 500-plus completed trials and Phase I capability. Cullman Clinical Trials is its north-central Alabama partner site. The pair gives Rovia owned density in a state it did not previously control. Gauge has funded the site roll-up since the 2024 platform launch. Separate from Reliable Medical, another Gauge healthcare vehicle. (Link)
  20. HealthEdge- and United Western–Backed Veridian Healthcare Acquires ScarScience from Mitchell-Vance Medical-grade silicone scar sheets and gels into plastic surgery, dermatology and physical-therapy channels. Brand add-on onto a wound-and-scar distribution platform rather than a clinic buy. Robert Friedberg remains CEO; Jessica Rowen stays on the seller side of the handoff. HealthEdge Investment Partners and United Western Group are the sponsors. (Link)
  21. Medallion acquires Andros, an NCQA-certified credentials verification organization, creating a credentialing platform covering more than one million providers. Medallion, a San Francisco AI-assisted credentialing and payer-enrollment platform, acquired Andros, an NCQA-certified CVO serving health plans, health systems, provider groups and telehealth companies since 2013. The combination brings more than one million providers across nearly 400 organizations and health plans onto one platform. Andros verifies data on more than 8 million providers and runs about 300,000 credentialing checks a year. Health-plan customers will move onto Medallion’s automated verification tools and AI outreach agents. (Link)
  22. Abry Partners–backed Centauri Health Solutions of Tempe, Arizona acquires Iowa-based Benny the Benefits Navigator to expand its SSI/SSDI eligibility technology. Centauri acquired Benny the Benefits Navigator, an Iowa startup founded in 2024 by Jeremy Shapiro, James Vancel and Joel Segre. Its AI platform replaces paper forms with a conversational digital intake for SSI and SSDI applications. Benny folds into Centauri’s Member Connect disability eligibility service, which already reaches more than 60 million lives. Latest add-on under Abry after the 2025 MedAllies purchase. (Link)
  23. Ignitus Recovery acquires AIM Health Boulder, a Colorado mental health and substance-use treatment program for young adults. Englewood-based Ignitus acquired AIM Health Boulder, a 20-year Boulder program treating adults 18–30 through PHP and IOP at the historic Earl House. Ignitus plans to keep existing programs and add residential treatment, alumni engagement and long-term recovery support. Founder Danny Conroy said he chose Ignitus to carry the program forward. CEO Steve Millette committed to no disruption for clients, staff or referral partners. (Link)
  24. Stony Brook Medicine Community Medical Group acquires South Shore Digestive Medicine, a Bay Shore, New York gastroenterology practice led by Dr. Darius Sorbi. The community physician arm of Stony Brook Medicine acquired South Shore Digestive Medicine in Bay Shore. Dr. Darius Sorbi trained in internal medicine at Stony Brook and completed his GI fellowship at Mayo Clinic. He specializes in advanced endoscopy, biliary and pancreatic disease and GI cancers. The practice is now listed at 10 Brentwood Road, Bay Shore, alongside Stony Brook GI sites in Commack and Lake Grove. Extends the SUNY-owned academic system’s coverage onto Long Island’s South Shore. (Link)
  25. AKTIV Against Cancer Merges with CancerFit Exercise-oncology combination. AKTIV is the U.S. sister of Norway’s Aktiv mot kreft — hospital gyms branded Pusterom in Norway and AKTIVcenter in the U.S., research funding at Memorial Sloan Kettering, first U.S. site at Summit Health in New Jersey. CancerFit is the digital and program counterpart. No price and no cap table on the open wire. Merger of two mission-aligned exercise-as-treatment platforms, not a clinic roll-up. (Link)
  26. Daia Orthodontics & TMJ Orthopedics acquires four former docbraces clinics in New Brunswick and Prince Edward Island, its first expansion outside the U.S. Rochester Hills, Michigan-based Daia acquired four clinics that previously operated under the docbraces name, in Grand Falls and Woodstock, New Brunswick, and Charlottetown and Summerside, Prince Edward Island. The founder-owned practice goes from one location to five. Founder Dr. Hadi Daia is certified in both the U.S. and Canada and has treated patients at these clinics since 2021, converting an existing clinical relationship into ownership. Current clinical and administrative teams stay. No outside sponsor was named. (Link)
  27. Medartis Holding (SIX: MED) Acquires M.A.R.C. Institute in Doral, Florida First permanent training site outside Europe and the group’s largest, with 36 surgical stations and capacity for 140 participants. Name and general manager Heloise Peixoto stay; the IBRA partnership continues; universities, societies and other device companies keep access. Satellite activity in São Paulo, Rio and Curitiba. Osteosynthesis implant maker buying education infrastructure, not a clinic roll-up. (Link)
  28. Xenetic Biosciences (NASD: XBIO) to Acquire Santersus AG in an All-Stock Exchange; Combined Company to Be Santersus Bio Agreement dated September 14, public print September 16. Swiss NucleoCapture blood-purification device plus Xenetic’s DNase platform against neutrophil extracellular traps. Santersus holders about 85%, Xenetic about 15% on a fully diluted basis. Pipeline includes Breakthrough Device-designated work in sepsis and SLE. Combined company expected to trade as Santersus Bio. Close targeted in the fourth quarter on a stockholder vote and Nasdaq listing of new shares. (Link)

Venture Deals and Other

  1. Vitruvian Partners leads Angle Health’s $600 million financing at a $2.7 billion valuation, with Town Hall Ventures, Blumberg Capital, Portage Ventures, Prudential Financial (NYSE: PRU)’s PruVen Capital and Y Combinator participating. London-based Vitruvian Partners led a $600 million equity financing in Angle Health at a headline $2.7 billion valuation. It combines a $200 million Series C with a $400 million tender offer for existing shareholders. New investor Town Hall Ventures joined existing backers Blumberg Capital, Portage Ventures, PruVen Capital and Y Combinator. The San Francisco company provides AI-driven health benefits to more than 5,000 small and mid-sized employers, with nearly $1 billion in annualized premiums. It reports 120% growth and four profitable quarters in a row. (Link)
  2. Thoreau leads a $100 million funding commitment to Penelope Health, with Bertelsmann Healthcare Investments, Twine Ventures and Seedcamp participating. Thoreau, the healthcare investment platform led by former New Mountain Capital president Matt Holt, has committed $100 million to London-based Penelope Health. Existing backers Bertelsmann Healthcare Investments, Twine Ventures and Seedcamp joined. The funding comes with a partnership to build shared infrastructure for real-time payments and clinical coverage rules. Penelope’s platform tracks insurer coverage policies for more than 200 million Americans across over 15,000 procedure and drug codes. The amount is a commitment rather than a closed round. (Link)
  3. JMI Equity leads Archy’s $50 million Series C, with TCV, Entrée Capital, Bessemer Venture Partners, CRV and Alven participating. JMI Equity led a $50 million Series C in Archy, a San Jose AI platform for running dental practices. Existing investors TCV, Entrée Capital, Bessemer, CRV and Alven joined. Total funding now stands at $97 million. Built-in AI agents handle claims and collections, visit notes, insurance eligibility, patient communications and analytics. Archy serves more than 1,000 practices in 45 states and processes over $300 million in payments a year. (Link)
  4. Catalio Capital Management leads AVAVA’s $45 million financing, made up of $30 million in equity and a $15 million debt facility. Catalio, AVAVA’s first institutional investor, led a $45 million package of $30 million in equity and a $15 million debt facility. The relationship includes $10 million of growth capital from Catalio’s Structured Opportunities Fund in 2024. Boston-based AVAVA sells aesthetic laser devices built on Focal Point Technology, which delivers energy to targeted depths in the skin. The money funds commercial expansion, new products and international growth. (Link)
  5. Obvious Ventures leads Mithrl’s $20 million Series A, with Headline and AGI House participating. Obvious Ventures led a $20 million Series A in Mithrl, a California company building AI infrastructure for drug developers. Headline, AGI House and several pharma executives participated. Its second-generation platform, Mithrl-1, pairs a proprietary biomedical model with agents that choose models and manage cost. It runs inside each client’s environment. The company says top-10 pharma companies and clinical-stage biotechs already use it, with a goal of 50% faster IND timelines. (Link)
  6. Neon leads Ayble Health’s $16 million Series A, with Unum Group (NYSE: UNM)’s Unum Ventures, Upfront Ventures, M13, Ohio-based Cleveland Clinic Ventures, DigiTx and Accomplice participating. Neon led an oversubscribed $16 million Series A in Boston-based Ayble Health. Total capital raised now exceeds $27 million. Ayble runs an AI-enabled virtual clinic for digestive conditions, sold to national health plans, large employers and benefit platforms. It reports a 47% average improvement in symptoms and at least a 3:1 return for customers. The money strengthens AI care tools and expands the company into autoimmune conditions. (Link)
  7. GOA Therapeutics Emerges from Stealth with $15.5 Million; Unveils GOA26 for Acute Alcohol Intoxication Dallas preclinical shop. In an IND-enabling porcine model after 1.2 g/kg oral ethanol, blood alcohol concentration was 61.3% lower versus control at 20 minutes. No FDA-approved drug rapidly lowers BAC today. IND targeted by year-end 2026; first-in-human work in 2027. Data were presented the same day at AAST in Dallas. (Link)
  8. Khosla Ventures leads Nara Health’s $14 million pre-seed and seed financing, with Long Journey Ventures and Superior Studios participating. Khosla led $14 million across pre-seed and seed in Nara Health, formerly Avant Health. Long Journey Ventures, Superior Studios and angels joined. The Chicago company administers health plans for self-insured employers using AI — benefits, claims, care coordination and member support. Nara has more than 25,000 members and has processed over $600 million in claims. CEO Sid Sinha said the money funds Chicago hiring and platform scale. (Link)
  9. Flare Capital Partners leads Kairon Health’s $5 million round, with Tau Ventures, Lightbank, General Advance and Pave Health Ventures participating. Flare led a $5 million round in Kairon Health, joined by Tau Ventures and existing backers Lightbank, General Advance and Pave Health Ventures. Founder Nick Bartz spent nine years at Aledade. The New York AI platform turns claims, records, admission alerts, lab and pharmacy data into task lists for staff at ACOs, health systems and physician groups. It covers more than one million patients across 30-plus states under Medicare, Medicaid and commercial value-based contracts. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update July 13th, 2026

LECO_Weekly-Healthcare-News_7-13-2026Download

Healthcare Weekly News and Deals –July 13th, 2026

  1. American Industrial Partners agreed to acquire Avanos Medical (NYSE: AVNS) in an all-cash take-private valued at approximately $1.272 billion. American Industrial Partners (AIP), an operationally oriented investor with roughly $17.8 billion in assets, is acquiring Avanos Medical (NYSE: AVNS) for $25.00 per share in cash — a ~72% premium to Avanos’s pre-announcement close — valuing the medical-technology company at about $1.272 billion enterprise value. Having cleared regulatory review, the deal is expected to close by late July 2026 following a July 22 stockholder vote. Alpharetta, Georgia-based Avanos, focused on specialty nutrition and pain-management/recovery devices, will become privately held. AIP plans to leverage its operational playbook to support Avanos’s next phase of innovation and commercial execution. (Link)
  2. TCW Steel City (part of PNC Financial Services Group, NYSE: PNC), alongside co-lenders Brightwood, CIFC and CalSTRS, provided a $170 million recapitalization financing to Colorado-based Lone Peak Dental Group. TCW Steel City — the private-credit platform combining PNC Financial Services Group (NYSE: PNC) and TCW Private Credit — served as lead arranger and administrative agent on a $170 million recapitalization of Lone Peak Dental Group, a Dental Partnership Organization operating 75-plus offices across 14 states. The facility bundled a term loan, revolver and delayed-draw term loan structured to bankroll future acquisitions. Brightwood, CIFC and CalSTRS joined as additional lenders. The senior-secured package reflects private-credit appetite for scaled, mission-driven dental platforms pursuing both de novo and affiliation growth, giving Lone Peak flexible capital to expand pediatric dental access across its footprint. (Link)
  3. Surplus Solutions, a portfolio company of private equity firm NMS Capital, acquired Frederick, Maryland-based DCM BioServices to expand its laboratory-automation technical-service capabilities. NMS Capital, a private equity firm managing more than $2.0 billion across business and healthcare services, added to its Surplus Solutions platform with the acquisition of DCM BioServices, a Frederick, Maryland provider of lab-automation maintenance, repair and integration. Terms were undisclosed. The tuck-in extends Surplus Solutions’ equipment-lifecycle-management model into recurring preventive-maintenance contracts — a stream NMS partner David Peterson framed as a natural extension of existing customer relationships. DCM services 3,000-plus instruments across 200-plus labs nationwide, deepening the platform’s technical bench across leading instrument makers and reinforcing NMS’s buy-and-build thesis in life-sciences services. (Link)
  4. Orthopedic & Balance Therapy Specialists, a seven-clinic Northwest Indiana outpatient physical-therapy practice, was sold to an undisclosed national rehabilitation platform. Orthopedic & Balance Therapy Specialists (OBTS), a seven-location outpatient physical-therapy provider founded in 2003 in Northwest Indiana, completed a sale to an unnamed national rehabilitation platform. Both financial terms and the acquiring platform were left undisclosed. The transaction fits the broader private-equity-driven consolidation of outpatient rehab, where scaled platforms continue absorbing founder-owned, multi-clinic practices with strong payer relationships and regional density. OBTS’s shareholders sought a strategic partner to preserve clinical standards and culture while accessing platform resources for continued growth, positioning the practice to expand within its market under larger ownership. (Link)
  5. EQT (Nasdaq Stockholm: EQT), through its EQT X fund, agreed to acquire the Corza Biosurgery/TachoSil business from Corza Medical, which is backed by private equity firm GTCR. EQT (Nasdaq Stockholm: EQT) agreed to acquire Corza Biosurgery — built around TachoSil, a dual-action hemostat-and-sealant surgical patch — from GTCR-backed Corza Medical. Financial terms were undisclosed; closing is expected in Q4 2026. Investing through its EQT X fund, EQT plans to accelerate U.S. commercial and indication expansion, broaden adoption in underpenetrated markets, and build a wider biosurgery platform via add-on M&A. GTCR, which carved out TachoSil in 2021 and combined it with Surgical Specialties, exits the unit. TachoSil is used across cardiovascular, hepatic, neurological and thoracic procedures in more than 50 countries. (Link)
  6. Onto Health, a fertility and longevity platform backed by ARTIS Ventures and Humania, acquired U.S.-based clinical-decision-support company LEVY Health. Onto Health — a physician-led fertility and longevity provider backed by ARTIS Ventures and Humania — acquired LEVY Health, a U.S. clinical-decision-support software company for reproductive medicine. Terms were undisclosed. The purchase follows Onto’s roughly $20 million Series A and provides the technological backbone for a scalable, tech-enabled fertility-care infrastructure spanning the United States and the Gulf Cooperation Council region. LEVY’s diagnostics help clinics identify endocrine disorders and streamline fertility workups, letting practices fold low-complexity fertility care into existing models. The deal signals investor appetite for AI-enabled infrastructure plays in the multi-billion-dollar global fertility-services market. (Link)
  7. ResMed (NYSE: RMD) agreed to sell its MatrixCare software business to private equity firm Frazier Healthcare Partners for $490 million in cash. ResMed (NYSE: RMD) agreed to divest its MatrixCare post-acute-care software unit to Frazier Healthcare Partners, a healthcare-focused private equity firm, in a $490 million all-cash deal expected to close in the first quarter of ResMed’s fiscal 2027. ResMed, which paid $750 million for MatrixCare in 2018, will redeploy proceeds toward shareholder returns via an accelerated share repurchase while sharpening its sleep-and-breathing focus. MatrixCare — serving 15,000-plus skilled-nursing, senior-living and home-health providers — generated roughly $220 million revenue and $55 million adjusted operating profit in fiscal 2026. Frazier, which has raised over $11 billion, gains a scaled long-term-care software platform. (Link)
  8. Steel Partners Holdings (NYSE: SPLP), a shareholder of InMode (NASDAQ: INMD), offered to acquire the medical-aesthetics company for $16.75 per share in cash, topping a competing CEO-led bid. Steel Partners Holdings (NYSE: SPLP), which owns roughly 1.3% of InMode (NASDAQ: INMD), launched an unsolicited $16.75-per-share all-cash offer for the Israeli medical-aesthetics maker — a 20% premium to the $13.95 unaffected price and $0.55 above a rival buyout led by CEO Moshe Mizrahy. Steel argued the CEO’s $16.20 bid undervalued InMode using a low 2026 EBITDA estimate, demanded Mizrahy’s removal over governance conflicts, and urged the board to form an independent committee. Steel also offered existing holders the option to roll up to 40% of their equity into the privatized company, intensifying the contested sale process. (Link)
  9. Emergency Care Partners — backed by private equity firms Varsity Healthcare Partners, MidOcean Partners and Regal Healthcare Capital Partners — partnered with Phoenix-based Empower Emergency Physicians. Emergency Care Partners (ECP), the largest single-specialty emergency-medicine physician-services provider in the U.S. and backed by Varsity Healthcare Partners, MidOcean Partners and Regal Healthcare Capital Partners, formed a strategic partnership with Empower Emergency Physicians, a Phoenix independent group serving Dignity Health’s St. Joseph’s hospitals. Terms were undisclosed. The deal extends Pensacola-based ECP’s Southwest footprint to more than 1.7 million annual patient encounters across ten states while preserving Empower’s physician-led model. It reflects the sponsors’ buy-and-build strategy of consolidating physician-owned groups under ECP’s infrastructure, building on MidOcean’s 2025 preferred-equity investment that funds continued acquisitions. (Link)
  10. Incline Equity Partners acquired a majority stake in medical and health physics testing provider West Physics from LNC Partners, which retains a minority interest. Incline Equity Partners acquired a majority equity interest in Atlanta-based West Physics, a provider of medical and health physics testing and consulting that certifies MRI, CT and X-ray equipment against ACR, IAC and Joint Commission standards across 6,000-plus client sites in all 50 states and abroad. Terms were undisclosed. Seller LNC Partners — which first invested in May 2018 and grew revenue more than 3.7x over seven years through organic expansion and six add-on acquisitions — rolls over a minority position alongside Incline. Founder-CEO Dr. Geoffrey West continues to lead, with both sponsors backing further organic growth and M&A into adjacent services and geographies. (Link)
  11. Cygnet Group, backed by parent company Universal Health Services (NYSE: UHS), acquired Orchard Care Group in the Republic of Ireland. Cygnet Group — the UK mental-health and social-care provider owned by Universal Health Services (NYSE: UHS) — acquired Orchard Care Group, an integrated fostering, residential and disability-care provider in the Republic of Ireland. Terms were undisclosed. Orchard operates 39 residential and community homes plus two day services and employs over 550 people, with its executive team staying on. The deal marks Cygnet’s first residential-support expansion beyond the UK, extending UHS’s international social-care reach. It follows Cygnet’s recent run of UK acquisitions and hospital builds, signaling continued consolidation of specialist care assets under the publicly traded U.S. hospital operator. (Link)
  12. HCC Healthcare signed a business-combination agreement with SPAC RF Acquisition Corp III (Nasdaq: RFAM) to pursue a Nasdaq listing at a roughly $500 million equity value. Singapore-incorporated HCC Healthcare, which runs integrated medical and long-term-care services through Taiwan subsidiaries, agreed to merge with RF Acquisition Corp III (Nasdaq: RFAM), a publicly traded special-purpose acquisition company, to go public on Nasdaq. The deal reflects a pre-transaction equity value of approximately $500 million at $10.00 per share, with closing targeted for Q4 2026 subject to shareholder and regulatory approvals. On a pro forma basis, the combined Taiwan-focused network spans 120-plus long-term-care facilities and 9,000-plus beds. The SPAC route gives HCC public-market capital to scale its aging-population care model across Taiwan, Japan and Asia. (Link)
  13. Austin, Texas-based private equity firm CenterGate Capital invested in Canadian Dental Labs (CDL), Canada’s leading manufacturer of dental prosthetics and orthodontic appliances. CenterGate Capital, an Austin, Texas private equity firm, made a control investment in Canadian Dental Labs (CDL), the Toronto-headquartered platform that is Canada’s leading maker of dental prosthetics and orthodontic appliances. Terms were undisclosed. CDL — comprising labs including Shaw Lab Group, Protec Dental and Hallmark — serves 5,000-plus dental professionals and DSOs nationwide, with CEO Ali Rezaei continuing to lead. CenterGate backs the platform’s next growth phase, funding investment in people, technology and its coast-to-coast laboratory network. The deal underscores private equity’s appetite for scaled, technology-forward dental-lab consolidators with recurring, patient-specific manufacturing demand. (Link)
  14. ReFocus Eye Health, the management-services organization backed by Zenyth Partners, partnered with Connecticut’s 11-location Solinsky EyeCare. ReFocus Eye Health — a Northeast ophthalmology management-services organization backed by investment firm Zenyth Partners — affiliated with Solinsky EyeCare, an 11-location comprehensive ophthalmology and optometry practice serving Greater Hartford, Connecticut. Terms were undisclosed. Adding Solinsky’s 14 ophthalmologists and optometrists lifts ReFocus’s network to more than 250 affiliated physicians across 114 locations in nine states. The affiliation preserves physicians’ clinical autonomy while providing operational and administrative support, reflecting Zenyth-backed ReFocus’s continued regional roll-up strategy. The transaction adds to a wave of private-equity-sponsored consolidation in eye care as platforms pursue density in attractive Northeastern markets. (Link)
  15. CONMED Corporation (NYSE: CNMD) is weighing a potential sale after receiving takeover interest from unnamed private equity firms. CONMED Corporation (NYSE: CNMD), a surgical-device maker focused on orthopedic and general surgery, saw shares jump as much as 10% after Bloomberg reported the company is exploring strategic options following acquisition interest from private equity firms. No formal sale process has been confirmed and specific bidders have not been disclosed. CONMED, whose products include sports-medicine implants, electrosurgery systems and the AirSeal platform, has been sharpening its focus on higher-margin surgical segments after exiting gastroenterology lines. The reported interest highlights sustained private-equity appetite for scaled medtech assets, though any transaction remains speculative pending confirmation of a formal review. (Link)
  16. Clarivate Plc (NYSE: CLVT) agreed to sell its Life Sciences & Healthcare segment to healthcare-focused investment firm Altaris LLC for $600 million. Clarivate Plc (NYSE: CLVT) agreed to divest its Life Sciences & Healthcare segment to Altaris LLC, an investment firm focused exclusively on healthcare, for $600 million. Clarivate receives $500 million cash at closing plus $25 million deferred, using proceeds to cut debt and sharpen its subscription-first focus on Academia & Government and Intellectual Property. The company expects a $225–250 million non-cash goodwill impairment. For Altaris, the carve-out delivers a data-and-analytics platform supporting decision-making across the drug and device lifecycle. The transaction reflects the recurring theme of publicly traded information providers shedding non-core units to specialist private-equity buyers. (Link)
  17. Private equity firm Warburg Pincus, partnering with the Abu Dhabi Investment Authority, is nearing a $7 billion-plus acquisition of specialty pharmacy PANTHERx Rare from owners General Atlantic, Nautic Partners and The Vistria Group. Warburg Pincus, which manages over $100 billion, is in advanced talks to acquire Pittsburgh-based specialty pharmacy PANTHERx Rare for more than $7 billion including debt, partnering with sovereign-wealth fund the Abu Dhabi Investment Authority. PANTHERx, focused on rare and orphan-disease medicines and patient support, is owned by a consortium of General Atlantic, Nautic Partners and The Vistria Group, which bought it from Centene in 2022. Nothing is finalized and timing could slip. The deal reflects private equity’s bet on recession-resistant, high-margin orphan-drug demand and the growing pattern of buyout firms pairing with sovereign-wealth capital on large checks. (Link)
  18. Halma plc (LSE: HLMA) acquired Summit Partners-backed Dreampath Diagnostics for an initial €154 million plus an earn-out of up to €121 million. UK-listed Halma plc (LSE: HLMA) acquired Dreampath Diagnostics, a Strasbourg-based provider of automated tissue-sample management systems for pathology labs, from growth-equity firm Summit Partners. Halma is paying an initial €154 million (about $132 million) in cash, with a performance-based earn-out of up to €121 million through 2028. Summit, which made an undisclosed growth investment in 2025, exits after helping Dreampath scale to 300-plus million samples across 500-plus labs in 50 countries. Dreampath — forecasting roughly €33 million revenue for the year to March 2027 — will run standalone within Halma’s Healthcare Sector, strengthening its diagnostics traceability capabilities. (Link)
  19. Spero Health — backed by Heritage Group, Health Velocity Capital, South Central Inc. and Frist Cressey Ventures — acquired CleanSlate Centers, backed by Granite Growth Health Partners, HealthQuest Capital and CRG. Spero Health, a Nashville-area outpatient addiction-treatment provider owned by Heritage Group, Health Velocity Capital, South Central Inc. and Frist Cressey Ventures, acquired multi-state opioid-treatment operator CleanSlate Centers — backed by Granite Growth Health Partners, HealthQuest Capital and CRG — in a deal that closed July 1 and averts CleanSlate’s shutdown. Spero assumed CleanSlate’s equity interests in exchange for taking on its debt and deal costs; terms were undisclosed. The combination roughly doubles Spero’s footprint to 128 locations across ten states, with heavy overlap in Ohio, Indiana and Kentucky, reflecting Spero’s thesis that consolidation strengthens payer leverage. (Link)
  20. Private equity firm Enhanced Healthcare Partners made a growth investment in LeadingReach, healthcare’s largest connected referral network. Enhanced Healthcare Partners (EHP), a healthcare-focused private equity firm, made a growth investment in Austin-based LeadingReach, operator of healthcare’s largest verified referral network spanning 30,000-plus organizations, 60,000-plus care settings and 125,000-plus providers processing 25,000 daily referrals. Terms were undisclosed. EHP adds experienced healthcare operators to LeadingReach’s board and provides resources to accelerate AI-powered automation, deeper EHR integrations and expanded network infrastructure following the company’s recent acquisition of iNaira Healthcare Technologies. The investment reflects EHP’s focus on founder-led health-IT platforms positioned to benefit from the industry’s shift toward value-based care and referral coordination. (Link)
  21. Shore Capital Partners, a healthcare-focused private equity firm, acquired Denver-based employee-benefits technology platform ThrivePass. Shore Capital Partners, a Chicago-based private equity firm with roughly $17 billion in assets, acquired ThrivePass, a Denver employee-benefits administration technology platform founded by Wade Rosen, Andreas Deptolla and Charles Shen. Terms were undisclosed. The investment funds continued development of ThrivePass’s configurable platform — spanning lifestyle spending accounts, rewards, tuition reimbursement, COBRA and pre-tax benefits for employers, brokers and PEOs. Shore brings healthcare-focused operational resources and a consolidation playbook to scale the business as demand grows for digital-first benefits tools. The deal extends Shore’s health-tech portfolio, targeting a lower-middle-market platform with organic and acquisition-driven growth potential. (Link)
  22. Integrity, LLC acquired Stride Health, the portable-benefits technology platform powering gig-economy insurance enrollment for partners including Uber, DoorDash and Amazon Flex. Dallas-based insurance distributor Integrity, LLC acquired Stride Health, a San Francisco portable-benefits technology platform that helps independent and gig workers enroll in health, dental, vision and life coverage. Terms were undisclosed. Stride — founded in 2014 and previously Allstate-backed — connects 4.6 million-plus workers and 140-plus enterprise partners including Uber, DoorDash, Gusto and Amazon Flex. Integrity folds Stride’s consumer marketplace into its IntegrityCONNECT agent platform and roughly 600,000-strong agent network, expanding into the under-65 individual market where tens of millions lack employer coverage. The deal pairs digital enrollment with agent-assisted distribution as worker-misclassification rules reshape portable-benefits demand. (Link)
  23. Principal Financial Group (Nasdaq: PFG) agreed to acquire digitally-native ancillary employee-benefits company Beam Benefits to expand its small-business protection platform. Principal Financial Group (Nasdaq: PFG) agreed to acquire Beam Benefits, a cloud-native ancillary employee-benefits company serving over 25,000 small businesses with dental, vision, life, disability and supplemental health coverage. Terms were undisclosed. Beam — built on an AI-powered underwriting and self-service technology stack and available in 46 states plus D.C. — generated roughly $175 million in premiums in 2025. Principal, which serves 180,000 employers, expects the deal to close in the latter half of 2026 and to lift Specialty Benefits premium and fee growth to at or above the high end of its 5–9% medium-term target in 2027. The digital-first model adds scalable capabilities to Principal’s SMB strategy. (Link)

Venture Deals and Other

  1. Valspring Capital led a $28 million Series B in Pediatrica Health Group, with participation from existing investor M33 Growth. Pediatrica Health Group, a Miami-based multi-site pediatric primary-care organization, closed a $28 million Series B led by Boston growth-equity firm Valspring Capital, with existing backer M33 Growth participating. The capital funds organic growth and strategic acquisitions plus investment in clinical infrastructure, technology and value-based-care capabilities. Pediatrica — founded through its partnership with M33 — has scaled to 21 locations across Florida and Texas. Valspring, formed by Bain Capital Ventures’ former healthcare team, cited its thesis that lasting healthcare change comes from companies innovating on patient and provider experience. The round backs continued expansion of equitable pediatric primary-care access. (Link)
  2. RPS Ventures led a $19 million Series B in Handspring Health, with new investor Angelini Ventures joining returning backers Cobalt Ventures, NextView Ventures, nvp capital, Hyde Park Angels and Cornucopian Capital. Handspring Health, a virtual youth mental-health provider, raised a $19 million Series B led by RPS Ventures, with new investor Angelini Ventures joining returning backers Cobalt Ventures, NextView Ventures, nvp capital, Hyde Park Angels and Cornucopian Capital. The round — lifting total funding to $37 million — funds clinician hiring, deeper value-based-care partnerships with payers, broader geographic reach and technology investment. Handspring, which employs rather than contracts its therapists and trains them in-house in evidence-based modalities, has treated 4,000-plus patients across nine states and grown revenue more than tenfold in two years. RPS’s Nancy Hilliker joins the board. (Link)
  3. Surface Ventures led a $3 million seed round in Octozi, with participation from Remarkable Ventures and following a prior investment from Debiopharm’s venture arm. Octozi, a New York agentic-AI company automating clinical-trial data operations for pharmaceutical sponsors, raised $3 million in seed funding led by Surface Ventures, with Remarkable Ventures participating and building on an earlier stake from Swiss pharma Debiopharm’s venture arm. The capital expands Octozi’s human-in-the-loop platform, which integrates with clinical systems to automate data cleaning, reconciliation, review and reporting. A peer-reviewed study found the tool boosted data-cleaning throughput roughly sixfold and cut reviewer error rates from about 55% to 8%, with estimated savings above $5 million per Phase III oncology trial. Surface Ventures’ Gyan Kapur framed the bet on compressing drug-development timelines. (Link)
  4. Andreessen Horowitz led a $50 million equity round for Pearl Health, joined by Viking Global Investors, AlleyCorp and Ulysses Capital, alongside a $60 million debt facility led by Trinity Capital (NASDAQ: TRIN). Pearl Health, a New York health-technology company enabling providers to manage risk for Medicare patients, raised $110 million — a $50 million equity round led by Andreessen Horowitz with Viking Global Investors, AlleyCorp and Ulysses Capital, plus a $60 million debt facility led by Trinity Capital (NASDAQ: TRIN). The capital funds AI-platform expansion, new risk products, Medicare Advantage entry and enterprise health-system and payer partnerships. Pearl — profitable in 2025 — supports 10,000-plus providers across 40-plus states serving 250,000-plus beneficiaries and manages roughly $3.6 billion in annualized medical spend. a16z’s Vineeta Agarwala praised Pearl’s technology-led approach to value-based payment. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jun 22nd, 2026

LECO_Weekly-Healthcare-News_6-22-2026Download
  1. Apollo Global-Backed Thoreau Group Signs Definitive Agreement for Strategic Growth Investment in Ensemble Health Partners, the Nation’s Largest RCM Managed Services Provider, at an Approximately $12 Billion Valuation Thoreau Group — the healthcare investment platform founded by former New Mountain Capital executive Matt Holt and backed by Apollo Global Management — signed a definitive agreement on June 17–18, 2026 to make a strategic growth investment in Ensemble Health Partners at an estimated $12 billion valuation. Ensemble manages more than $55 billion in net patient revenue annually across 200+ hospitals and approximately 12,000 employees, serving major health systems through billing, payment, and AI-enabled RCM services — including an RCM-native large language model developed in partnership with Cohere — following a $4.75 billion dividend recapitalization completed in January 2026. Legacy investors Berkshire Partners, Warburg Pincus, and Bon Secours Mercy Health will continue as co-investors. The transaction positions Thoreau at the center of the scaled healthcare administrative outsourcing sector. (Link)
  2. Abry Partners has closed a $780 million single-asset continuation fund anchored by Neuberger Berman and Apollo S3 (NYSE: APO) to retain its investment in Centauri Health Solutions, while simultaneously divesting Centauri’s Provider Solutions business to Elevate, a portfolio company of Audax Private Equity and Parthenon Capital Partners. Boston-based private equity firm Abry Partners orchestrated a $780 million single-asset continuation fund to extend its ownership of Centauri Health Solutions — a healthcare technology company serving U.S. health plans and health systems — transferring the asset from Abry Fund IX into the new vehicle. The Continuation Fund was co-anchored by Neuberger Berman and Apollo S3 (NYSE: APO), with additional commitments from Abry’s existing LP base. Concurrently, Centauri’s Provider Solutions business was divested to Elevate, a portfolio company of Audax Private Equity and Parthenon Capital Partners, sharpening Centauri’s focus as a pure-play payer technology and data intelligence platform. Since Abry’s 2020 investment, Centauri’s payer business tripled revenue and quadrupled EBITDA. (Link)
  3. Altaris has agreed to acquire Simulations Plus (Nasdaq: SLP) for approximately $375 million in an all-cash transaction, representing a 26% premium to the company’s 60-day volume-weighted average price, with the deal expected to close in Q4 2026. New York-based Altaris, an investment firm managing over $9 billion in equity capital with an exclusive focus on healthcare, has entered into a definitive agreement to acquire Simulations Plus (Nasdaq: SLP) at $18.50 per share in cash. Altaris anticipates combining the target with Chemical Computing Group (CCG), an existing Altaris portfolio company focused on molecular design software, to create a more integrated AI-driven drug development platform. The all-cash transaction, unanimously approved by Simulations Plus’s board, is financed through committed equity and debt from Altaris-affiliated funds without a financing contingency. Simulations Plus co-founder Dr. Walter Woltosz has entered into a voting support agreement backing the deal. The transaction is expected to close in Q4 2026 subject to stockholder and regulatory approvals. (Link)
  4. Abarca Health and LucyRx Announce Strategic Combination to Create the Only Modern PBM Built for Commercial and Government Scale Abarca Health and LucyRx have announced a strategic combination to form a modern, independent pharmacy benefit manager (PBM) with the scale and technology to serve commercial and government clients nationwide. The combined entity, operating under the parent brand Healthcare Revolution Partners, will provide prescription services to more than 9 million members. Abarca contributes its Darwin Healthcare Intelligence platform — a cloud-native, configurable PBM technology stack — while LucyRx brings clinical capabilities and deep expertise serving employers and labor groups. Both brands will continue operating as subsidiaries with no disruption to clients or members. The combination arrives amid ongoing scrutiny of traditional PBM consolidation and demand for transparent, independent alternatives. (Link)
  5. Singlepoint Healthcare Acquires Healix, Expanding National Infusion Capabilities Singlepoint Healthcare has acquired Healix, a leading provider of outpatient infusion management services operating more than 220 physician-owned and ambulatory infusion centers nationwide. The deal enhances Singlepoint’s integrated care model for inflammatory diseases by adding specialized infusion services spanning infectious disease, gastroenterology, neurology, rheumatology, and related therapeutic areas. This marks Singlepoint’s third acquisition in the past year, reflecting an accelerated buy-and-build strategy in the outpatient infusion market — a high-growth segment driven by biosimilar adoption, site-of-care migration from hospitals to lower-cost settings, and increasing prevalence of chronic inflammatory conditions. Healix will continue its focus on optimizing patient care in outpatient settings following integration. (Link)
  6. Aldrich Capital Partners-backed Compliancy Group has acquired Healthicity, a leading provider of healthcare compliance and auditing software, to create the most comprehensive combined platform for healthcare compliance programs serving more than 3,000 healthcare organizations. Compliancy Group, the healthcare compliance SaaS platform backed by growth equity investor Aldrich Capital Partners, has acquired Healthicity, a provider of healthcare auditing and compliance software including Compliance Manager and Audit Manager+ solutions. The combination creates the first unified platform delivering end-to-end coverage of provider, coding, and documentation auditing alongside workforce compliance, risk assessment, and incident management for a combined customer base exceeding 3,000 U.S. healthcare organizations (Link)
  7. ChartSpan Acquires Validic, the Leading Personal Health Data Platform, Creating a Unified Clinical Care Management and Remote Patient Monitoring Platform for Health Systems, Payers, and Life Sciences Companies Greenville, SC-based ChartSpan, a leading care management services company, announced on June 22, 2026 the completed acquisition of Validic, the healthcare industry’s leading personal health data platform connecting wearable and clinical devices to health system workflows. The combined company unites ChartSpan’s clinical care teams and Chronic Care Management, Advanced Primary Care Management, and Remote Patient Monitoring services with Validic’s global IoT and health data API infrastructure, device logistics, and RPM software — enabling organizations to move from periodic observation to continuous patient understanding. (Link)
  8. Ohio-based Align Capital Partners’ portfolio company Premier Biotech (based in Cleveland, Ohio and Dallas, Texas) has acquired both NexScreen and TransMed, representing the firm’s seventh acquisition since partnering with ACP in November 2022. Cleveland, Ohio-based Align Capital Partners (ACP), a growth-oriented private equity firm managing $3.2 billion in committed capital, has executed two simultaneous bolt-on acquisitions through its drug and alcohol testing portfolio company Premier Biotech: NexScreen, a point-of-care diagnostic testing solutions provider operating across the U.S., Australia, and New Zealand; and TransMed, a broad-catalog drug testing and lab supply distributor with over 1,000 direct customer accounts and a global e-commerce platform. These transactions mark Premier Biotech’s sixth and seventh acquisitions under ACP’s ownership since November 2022, extending the company’s international footprint and product offering across healthcare, government, and workplace markets. (Link)
  9. Cleargate Capital Partners has made a strategic investment in Fellow Health Partners, a Bay Shore, New York-based provider of revenue cycle management services to more than 500 clinicians across approximately 50 healthcare organizations nationwide. Healthcare-focused private equity firm Cleargate Capital Partners, founded in 2025, has made an undisclosed strategic investment in Fellow Health Partners, a leading RCM services provider to physician groups, ambulatory surgery centers, and specialty healthcare organizations across the U.S. Cleargate’s investment is intended to fund growth across Fellow’s SAVi technology platform,capital to pursue add-on acquisitions. Fellow’s existing management team, led by CEO Michael N. Brown, will continue to lead the organization. The deal supports Cleargate’s thesis of backing founder-led, lower-middle-market healthcare businesses with partnerships. (Link)
  10. AI-Native Medicare Navigation Platform Connie Health Completes Acquisition of Clearlink’s Medicare Business — Its 10th Acquisition — Alongside a $40 Million Series B Led by HealthQuest Capital, Bringing Total Funding to $85 Million Boston-based Connie Health, the AI-native Medicare navigation platform, has completed its acquisition of Clearlink Insurance Agency’s Medicare business — its 10th acquisition — while closing a $40 million Series B led by HealthQuest Capital with participation from JSL Capital, Khosla Ventures, aMoon, and Pitango HealthTech. The round brings total funding to $85 million. The integration leverages Connie’s AI and automation platform to seamlessly absorb the large-scale book while maintaining personalized service through its network of local trusted agents. Capital will support continued national expansion, technology investment, and additional acquisitions as Connie deepens its role as a strategic partner for value-based care organizations and ACOs. (Link)
  11. Tredence Acquires KMK Consulting, a Morris Plains, NJ-Based Life Sciences Analytics Firm Serving 8 of the World’s Top 10 Pharmaceutical Companies, to Build a Scaled Healthcare and Life Sciences AI Platform Tredence, a global AI and data science solutions firm, has acquired KMK Consulting, a specialized analytics and consulting firm with deep expertise in pharmaceuticals and life sciences headquartered in Morris Plains, New Jersey. KMK partners with 8 of the world’s top 10 pharmaceutical companies and brings over two decades of domain expertise in commercial analytics, real-world evidence (RWE), and market research. The deal positions Tredence to expand its Healthcare & Life Sciences business by combining KMK’s domain depth with Tredence’s Agentic AI capabilities across the full molecule-to-market development journey. (Link)
  12. Interlock Equity-Backed VeloSource Simultaneously Acquires Quest Locum Tenens and Syncx LLC, Adding National Physician Staffing Scale and a Proprietary Vendor-Neutral Workforce Management Technology Platform St. Louis-based VeloSource LLC, a portfolio company of Interlock Equity, has acquired Quest Locum Tenens and Syncx LLC to build an enterprise healthcare workforce ecosystem. The deals expand VeloSource’s national clinical staffing capabilities and add Syncx’s proprietary vendor-neutral technology platform for workforce management, including a differentiated physician float pool model that digitizes scheduling and prioritizes internal resources before external placement. Quest brings additional nationwide placement expertise for physicians, nurse practitioners, physician assistants, and CRNAs. The combined platform aims to address clinician shortages and improve operational efficiency for healthcare organizations. (Link)
  13. Avista Healthcare Partners-backed EBI has acquired Xstim, a division of Precision Medical Products Inc., to expand its bone growth stimulation portfolio and reinforce its position as the only pure-play bone growth stimulation company. EBI, a portfolio company of New York-based Avista Healthcare Partners — which has invested over $10 billion across more than 50 healthcare businesses globally — has acquired Xstim, the bone healing division of Precision Medical Products Inc. Xstim’s next-generation, wearable, capacitively coupled electrical stimulation therapy for lumbar spinal fusion is highly complementary to EBI’s existing FDA-approved portfolio of implantable and non-invasive bone healing solutions, including the EBI® Bone Healing System, OrthoPak®, and SpinalPak®. The deal advances Avista’s strategy of building differentiated, growth-oriented healthcare product platforms with clear scale potential and broadens EBI’s total addressable market across spinal fusion, nonunion fracture, and joint fusion applications. (Link)
  14. HR HealthCare Acquires SteriGear LLC and Fig Leaf Brand, Expanding Urology Solutions Across the Care Continuum York, PA-based HR HealthCare has acquired SteriGear LLC, including the Fig Leaf brand of urinary drainage devices and related covers and drapes, to strengthen its bladder management portfolio across acute, post-acute, and home care settings. The Fig Leaf product emphasizes patient dignity with privacy features, while SteriGear’s solutions complement HR HealthCare’s TruCath line. The deal creates a more comprehensive urology platform accessible through a single source, consolidating procurement for hospital systems and post-acute care providers. The Fig Leaf brand will continue operating under its existing name, with the SteriGear brand transitioning into HR HealthCare’s portfolio over time. (Link)
  15. Michigan Ear Institute Partners with Align ENT & Allergy, Expanding Access to Specialized Ear, Hearing, and Balance Care Across Michigan and Ohio Under a Physician-Led MSO Model Michigan Ear Institute (MEI), headquartered in Farmington Hills, Michigan, has entered into a strategic partnership with Align ENT & Allergy, a physician-led management services organization. The transaction closed on March 25, 2026, and expands access to specialized ear, hearing, and balance care across Michigan and Ohio. MEI operates four locations and is recognized for advanced diagnostic and treatment options. The partnership aligns MEI with Align’s MSO model focused on operational support, billing, and practice management while preserving full clinical autonomy for its physicians. (Link)
  16. Brightstar Capital Partners Acquires Erdman, a Madison, WI-Based Architecture and Engineering Firm Specializing in Healthcare Facilities and Senior Living Communities, to Expand Its Architecture and Design Platform Brightstar Capital Partners has acquired Erdman, a Madison, Wisconsin-based architecture and engineering firm founded in 1951 specializing in healthcare facilities and senior living communities. Licensed in more than 45 states, Erdman joins KZF Design in Brightstar’s architecture and design platform and contributes its proprietary ZeroIn healthcare analytics platform — a data-driven tool for optimizing facility design and operational performance. The deal supports growing demand for healthcare and senior living construction driven by an aging population and expands Brightstar’s national footprint in healthcare facility design and development. (Link)
  17. PruittHealth Acquires Four Home Health Offices in South Georgia, Adding 36 Counties to Expand Its Statewide Service Area to 109 Counties Under the PruittHealth @ Home Brand PruittHealth has acquired four home health offices in South Georgia — Community Health Services of Georgia locations in Vidalia and Albany, and Georgia Home Health Services locations in Valdosta and Tifton — adding 36 counties to its service area for a total of 109 counties statewide. The acquired offices will operate under the PruittHealth @ Home brand and integrate into PruittHealth’s existing home health network. This expansion reinforces PruittHealth’s position as a leading provider of home health services across Georgia, continuing the organization’s strategy of geographic densification within its core market through targeted acquisitions of established home health agencies. (Link)
  18. Jennie Stuart Health Acquires Six Medical Practices Across Western Kentucky, Including Generations Primary Care, MDVIP, Hopkinsville Family Care, and Three Additional Clinics, Strengthening Regional Provider Coordination Jennie Stuart Health has acquired six medical practices — Generations Primary Care, MDVIP, Hopkinsville Family Care, Western Kentucky Pulmonary Clinic, Elkton Clinic, and Crofton Clinic — to expand access to primary and specialty care across western Kentucky. Patients will continue receiving care from the same providers at their current locations with no interruption in services, and MDVIP will maintain its existing direct primary care membership model. The acquisition strengthens provider coordination, improves specialist access, and supports the long-term stability of regional healthcare delivery in underserved rural and semi-rural Kentucky communities. (Link)
  19. Legend Senior Living Acquires Apple Blossom Senior Living in Moon Township, Pennsylvania, Expanding to 78 Residences Across Eight States as Part of Its Ongoing Pennsylvania Growth Strategy Legend Senior Living has acquired Apple Blossom Senior Living in Moon Township, Pennsylvania, as part of its ongoing Pennsylvania expansion. The community offers Independent Living cottages along with Personal Care and Memory Care options. With this addition, Legend now operates 78 senior living residences across eight states. The acquisition strengthens Legend’s presence in the greater Pittsburgh market and continues its family-led approach focused on personalized resident support, dignity, and quality of life. Legend’s acquisition strategy targets established communities in growing suburban markets where demand for senior living services is supported by favorable demographic trends. (Link)
  20. Imagen Dental Partners Adds Pineview Aesthetic & Family Dentistry in Bellevue, Washington, Expanding Its Pacific Northwest Presence with a Practice Founded in 2007 by Repeated Seattle Top Dentist Honoree Dr. Gannon Stahl Imagen Dental Partners has partnered with Pineview Aesthetic & Family Dentistry, a leading Bellevue, Washington practice founded in 2007 and led by Dr. Gannon Stahl, a University of Washington School of Dentistry graduate and repeated Seattle Top Dentist honoree. The practice offers comprehensive family, cosmetic, restorative, and implant dentistry using advanced clinical technology and a patient-first approach. Dr. Stahl will continue focusing on clinical excellence while gaining access to Imagen’s support infrastructure across recruiting, marketing, revenue cycle management, and operations — a structure consistent with the supported independence model common across dental service organization partnerships. (Link)
  21. New Jersey Medical Office Building and ASC Portfolio — Including Physician’s SurgiCenter — Sells for $13.6 Million; Two-Building Medical Portfolio in Toms River 99% Leased at Close A medical office building portfolio in Toms River, New Jersey, including Physician’s SurgiCenter, has sold for $13.6 million. The two-building Holiday City Medical Portfolio totals 55,680 square feet and was 99% leased at closing, with established tenants including Labcorp, University Radiology Group, Asetera Cancer Care, Premier Dermatology, Elite Podiatry, and several others. Horizon Equities sold the properties to an undisclosed buyer following strong investor interest, with nearly a dozen competing offers received. The transaction reflects continued investor appetite for stabilized, multi-tenant medical office and ambulatory surgery center assets in established suburban New Jersey healthcare markets. (Link)
  22. Group Benefit Services Acquires Integrity Administrators, a Sacramento, CA-Based Third-Party Administrator, Expanding Its Self-Funded Health Plan Administration Platform with Enhanced Nurse Navigator and Member Services Capabilities Group Benefit Services, Inc. (GBS) has acquired Integrity Administrators, Inc. (IAI), a third-party administrator based in Sacramento, California specializing in self-funded health plan administration. The combination enhances GBS’s platform with expanded resources, Nurse Navigator programs, and a high-touch service model focused on cost savings and member support. IAI clients will benefit from GBS’s broader infrastructure and national network while maintaining the personalized service approach that defines the IAI model. The transaction continues consolidation in the fragmented TPA market, where self-funded employers increasingly seek scaled administrators with clinical care coordination capabilities alongside traditional plan administration services. (Link)

Venture Deals and Other

  1. Samsung Electronics (KRX: 005930) has made a $175 million investment in Element Biosciences’ upsized Series E financing round, becoming the genomic and multiomic technology company’s largest shareholder, with an undisclosed amount from other co-investors also participating. Samsung Electronics (KRX: 005930) has committed $175 million into an upsized Series E financing round for Element Biosciences, a San Diego-based life sciences company specializing in DNA sequencing and multiomic technologies. Samsung, a longstanding investor in Element, will become its largest shareholder upon close, pending regulatory approvals. The investment reflects Samsung’s strategic confidence in Element’s growing product ecosystem — including AVITI, VITARI, and the forthcoming AVITI Dx and AVITI24 — and aligns with its broader precision medicine and life sciences innovation mandate. Proceeds will fund global commercialization, geographic expansion, and advancement of the company’s product roadmap across research, translational science, and diagnostic applications. (Link)
  2. Avataar Ventures has led a $28.5 million Series B round in Bengaluru-based deep-tech manufacturing startup Ethereal Machines, with participation from existing investor Peak XV Partners, to fund a new manufacturing facility, indigenous CNC technology development, and global market expansion. Bengaluru-based deep-tech firm Ethereal Machines has raised $28.5 million in a Series B round led by Avataar Ventures, with Peak XV Partners participating as a returning investor. The capital, arriving nearly two years after the company’s $13 million Series A, is earmarked to construct a new 300,000-square-foot automated manufacturing plant under an MOU with the Karnataka government, develop a proprietary multi-axis CNC controller, and expand into the U.S. and European markets. Ethereal Machines’ MaaS business has grown threefold year-on-year since its Series A and production capacity has expanded tenfold. The company targets sectors including aerospace, defense, semiconductor manufacturing, and consumer electronics. (Link)
  3. Echo Health Ventures and FMZ Ventures have co-led a $30 million Series C in InStride Health, with existing investors Valtruis, .406 Ventures, General Catalyst, and Mass General Brigham Ventures also participating, bringing the pediatric mental health company’s total raised to $86 million. InStride Health, a provider of insurance-based virtual specialty treatment for children, teens, and young adults with anxiety and OCD, has closed a $30 million Series C co-led by Echo Health Ventures — the strategic CVC arm of the Blue Cross Blue Shield collaborative network — and FMZ Ventures, a growth equity firm specializing in digitally enabled consumer marketplace companies. Existing investors Valtruis, .406 Ventures, General Catalyst, and Mass General Brigham Ventures also participated. The round brings InStride’s total capital raised to $86 million and will fund geographic expansion from 17 states to Midwest and Western markets and deepening of payer relationships with insurers including Aetna, Anthem, Cigna, and UnitedHealthcare. (Link)
  4. Index Ventures has led a $7 million seed round in Uncovr, with Seedcamp, Frst, No Labels Ventures, and Entrepreneurs First also participating, to fund the AI surgical documentation startup’s expansion across U.S. and European hospital systems. Uncovr, a surgical AI company that analyzes intraoperative video to automatically generate procedural coding and operative reports, has secured $7 million in seed funding led by Index Ventures, with Seedcamp, Frst, No Labels Ventures, and Entrepreneurs First among additional investors. Digital Surgery founder Jean Nehme, Color Health CEO Othman Laraki, and Meta board member Charlie Songhurst also contributed individually to the round. Uncovr, launched in 2025 and currently deployed across more than 400 operating rooms in the U.S. and Europe, has identified a 16% missed-billable-step rate and a ~10% reimbursement gap in procedures. The seed capital will be deployed to hire ML engineers and expand hospital partnerships. (Link)
  5. Bonfire Ventures, Supernode, Comma Capital, and individual investor Jacquelyn Kung have backed Vali Health with $6 million in funding as the San Francisco-based AI home care startup emerges from stealth. Vali Health, a San Francisco-based startup building AI infrastructure for the home care industry, has emerged from stealth with $6 million in funding from Bonfire Ventures, Supernode, Comma Capital, and individual investor Jacquelyn Kung. Founded by Serena Dang (CEO) and Jason Wu (CTO), Vali Health has built an AI-native 24/7 safety infrastructure designed to help mid-sized home care agencies automate workforce management and coordination, saving upwards of 20 hours per week. The startup has achieved 400% growth in just 12 months, now serving agencies across nearly 100 locations in 30 states. Capital will be used to expand operations and market reach. (Link)
  6. Vanna Health Raises $17 Million to Expand Evidence-Based Care for People Living with Serious Mental Illness Vanna Health, a value-based health technology company providing integrated mental and chronic health support through community-based coaching, has raised $17 million in funding co-led by a national healthcare insurer and AlleyCorp, with participation from Health Velocity Capital. The capital will support expansion of its clinical reach, technology infrastructure, and recovery-oriented care model for individuals with serious mental illness (SMI) such as schizophrenia and bipolar disorder. Vanna Health currently operates in four states and aims to scale its community-centered, technology-enabled approach nationwide. (Link)
  7. Khosla Ventures has led an $11 million seed round in Clair Health, with participation from a16z Speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC, and Anne Wojcicki, to develop the first continuous, non-invasive wearable hormone monitor for women. Clair Health, a femtech startup co-founded by Stanford graduates Jenny Duan and Abhinav Agarwal, has raised $11 million in seed funding led by Khosla Ventures, with a16z Speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC, and 23andMe co-founder Anne Wojcicki also contributing. The startup is building a wearable wristband leveraging a proprietary stack of 10 biosensors — including biomagnetic sensors not found in any competing consumer wearable — combined with AI models to continuously infer a woman’s hormonal cycle phase without blood draws or skin piercing. With a 25,000-person waitlist and a sold-out presale, Clair Health plans a November 2026 wellness product launch and subsequent pursuit of FDA clearance for applications across fertility, perimenopause, and hormone conditions. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update May 11th, 2026

LECO_Weekly-Healthcare-News_5-11-2026Download
  1. Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease Angelini Pharma S.p.A., an international pharmaceutical company and part of Italy’s Angelini Industries Group, entered into a definitive agreement to acquire Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), a Coral Gables, FL-based commercial-stage biopharmaceutical company focused on rare and difficult-to-treat diseases, in an all-cash transaction valued at approximately $4.1 billion or $31.50 per share. The deal, announced May 7, 2026, represents a premium to Catalyst’s recent trading prices and will expand Angelini Pharma’s U.S. market presence and rare-disease portfolio, particularly in brain health and neurological conditions. Closing is expected in the third quarter of 2026, subject to Catalyst stockholder approval, regulatory clearances, and other customary conditions. (Link)
  2. Roche Holding AG (SIX: RO, ROP; OTCQX: RHHBY), the Swiss pharmaceutical and diagnostics giant, entered into a definitive merger agreement to acquire PathAI, a Boston-based AI-powered digital pathology company, for USD 750 million upfront plus up to USD 300 million in milestone payments, valuing the deal at up to USD 1.05 billion. Roche (SIX: RO, ROP; OTCQX: RHHBY) has signed a definitive merger agreement to acquire Boston-based digital pathology firm PathAI. Under the terms of the agreement, Roche will pay a purchase price of USD 750 million upfront and additional milestone payments of up to USD 300 million, bringing total potential consideration to USD 1.05 billion. Roche has partnered with the company since 2021, expanding their agreement in 2024 to include the development of AI-enabled companion diagnostic algorithms. Roche Diagnostics will absorb PathAI as an operating unit after closing expected in H2 2026, pending regulatory clearance, accelerating Roche’s AI-powered diagnostics capabilities. (Link)
  3. Cross Country Healthcare, Inc. (NASD: CCRN), a Boca Raton-based technology-driven healthcare workforce solutions company, entered into a definitive agreement to be acquired by growth-oriented private equity firm Knox Lane in an all-cash transaction valued at approximately $437 million, or $13.25 per share. Cross Country Healthcare (NASDAQ: CCRN) has signed a definitive agreement to be taken private by Knox Lane, a growth-oriented investment firm, in an all-cash transaction valued at $437 million, or $13.25 per share. The price represents a premium of approximately 31% to CCRN’s closing price on May 6, 2026, and a 45% premium to its 90-day volume-weighted average trading price. Knox Lane is a private equity firm with $3.5 billion in assets under management. Upon completion, Cross Country Healthcare will become a privately held platform company in Knox Lane’s portfolio and will cease trading on Nasdaq, with closing expected in Q3 2026.  (Link)
  4. Sanford Health, a Sioux Falls, South Dakota-based nonprofit rural health system, and North Memorial Health, a Twin Cities-based Minnesota nonprofit health system, signed a definitive agreement to combine into a single nonprofit organization, supported by a planned $600 million investment. Sanford Health and North Memorial Health have signed a definitive agreement to combine into a single nonprofit health system. The transaction includes a $600 million investment in Twin Cities services. Sanford’s most recent annual revenue was nearly $11.7 billion in 2025, which reflects its merger with Marshfield Clinic Health System in Wisconsin. Sanford Health President and CEO Bill Gassen will continue to serve as president and chief executive officer of the combined organization. The partnership is expected to close sometime this year, subject to completion of regulatory processes and other customary closing conditions. (Link)
  5. The University of Pittsburgh Medical Center (UPMC), a Pittsburgh-headquartered nonprofit health care provider and insurer, and CommonSpirit Health, one of the nation’s largest nonprofit Catholic healthcare organizations, signed a definitive agreement transferring ownership of Steubenville, Ohio-based Trinity Health System to UPMC. UPMC and CommonSpirit Health have signed a definitive agreement transferring ownership of Trinity Health System to UPMC. The transfer includes Trinity West, Trinity East, Trinity St. Clairsville Neighborhood Hospital, Trinity Twin City Medical Center, and associated clinics, to UPMC. The transaction is expected to be completed in Fall 2026, pending regulatory review and customary closing conditions. The deal will allow UPMC to expand into the Midwest from its foothold in the mid-Atlantic. Financial terms were not disclosed. The deal marks UPMC’s first expansion into Ohio while supporting CommonSpirit’s multiyear asset-divestiture turnaround strategy. (Link)
  6. agilon health, inc. (NYSE: AGL), an Austin, TX-based value-based care platform partnering with primary care physicians on Medicare Advantage, saw its stock surge after delivering Q1 2026 revenue of $1.42 billion and GAAP EPS of $1.80, prompting upgrades from Deutsche Bank and Jefferies. agilon health (NYSE: AGL) shares surged sharply following a Q1 2026 earnings beat. Revenue came in at $1.42 billion versus analyst estimates of $1.38 billion, EPS (GAAP) of $1.80 crushed the consensus of $0.83, and Adjusted EBITDA of $53.84 million beat estimates of $36.15 million by nearly 49%. Deutsche Bank upgraded agilon health’s stock rating to Buy from Hold, raising its price target to $49.00, while Jefferies also upgraded the stock to Buy. For the full year, the company raised its 2026 Adjusted EBITDA guidance to $10–$40 million, with new CEO Tim O’Rourke commencing leadership. (Link)
  7. Addus Enters Indiana With HomeCourt Acquisition, Lines Up Second Deal Addus HomeCare Corporation (NASDAQ: ADUS), a Frisco, Texas-based provider of home and community-based personal care services, acquired HomeCourt Home Care, a Fort Wayne, Indiana-based non-medical home care agency. Addus HomeCare has entered the Indiana market through the acquisition of HomeCourt Home Care. The deal adds approximately $9.8 million in annualized revenue and expands Addus’ footprint into the Midwest with a strong regional provider of in-home personal care and supportive services for elderly and disabled clients. The transaction closed on May 1, 2026 and marks Addus’ continued geographic expansion strategy in the home-care sector. Financial terms were not disclosed. (Link)
  8. HealthVerity, Inc., a Philadelphia-based leader in privacy-protected real-world data exchange and patient identity solutions, entered into a definitive agreement to acquire Symphony Health Solutions Corporation, a commercial healthcare data and analytics business formerly part of ICON plc (NASDAQ: ICLR). HealthVerity has announced the acquisition of Symphony Health to combine its clinical data depth with Symphony’s commercial insights, creating a unified, AI-ready platform for life sciences, payers, and government entities. The transaction, announced on May 5, 2026, is expected to close in May 2026 subject to customary closing conditions. Financial terms were not disclosed. (Link)
  9. Elsevier completes acquisition of Mytonomy and introduces comprehensive end to end patient engagement solutions for healthcare providers. Elsevier, a global leader in scientific publishing and health information solutions (part of RELX plc), completed the acquisition of Mytonomy, Inc., a Washington, D.C.-based provider of cloud-based video patient engagement and education platforms for hospitals and health systems. Elsevier has completed the acquisition of Mytonomy to integrate its clinical content libraries with Mytonomy’s video-first patient engagement platform, creating end-to-end solutions that improve adherence, reduce readmissions, and support value-based care across the care continuum. The deal, closed on May 5, 2026, combines Elsevier’s trusted evidence-based content with Mytonomy’s HIPAA-compliant, personalized video and interactive tools already deployed at more than 300 U.S. healthcare organizations. Financial terms were not disclosed. (Link)
  10. CQ Medical, the Avondale, Pennsylvania-based global leader in radiotherapy positioning solutions formed in 2022 through the combination of CIVCO Radiotherapy and Qfix, acquired .decimal, a Sanford, Florida-based precision manufacturer of patient-specific radiotherapy beam-shaping devices. CQ Medical has acquired .decimal to expand its patient-specific cancer treatment portfolio. CQ Medical was formed in 2022 through the combination of CIVCO Radiotherapy and Qfix, bringing together decades of expertise in essential radiation therapy positioning and immobilization solutions. Serving the radiotherapy clinical community for more than 40 years, .decimal is a trusted partner known for its rapid production of customized, patient-specific devices—typically manufactured and shipped within 1–2 days of order receipt. To date, the company has delivered over 500,000 patient-specific treatment devices, and actively serves more than 900 cancer centers across the United States. Financial terms were not disclosed. (Link)
  11. Med Tech Solutions (MTS), a Valencia, California-based managed healthcare IT services provider and portfolio company of Silversmith Capital Partners, acquired Avarion (formerly Huntzinger Management Group), a two-time Best in KLAS healthcare IT advisory firm, to span the full care continuum. Silversmith Capital Partners-backed Med Tech Solutions has acquired Avarion to strengthen its managed services platform. Med Tech Solutions, a provider of managed healthcare IT services and a portfolio company of Silversmith Capital Partners, acquired Avarion, a healthcare IT advisory firm serving hospitals, health systems and care networks. The combination unites MTS’ EHR managed services, application support, and technology infrastructure expertise with Avarion’s deep experience in healthcare IT advisory, consulting, and leadership services. Robert Kitts, Avarion’s CEO and founding partner, will report to Mona Abutaleb, CEO of MTS, and lead the company’s strategic advisory and staffing services. Financial terms were not disclosed. (Link)
  12. TimelyCare, a Fort Worth, TX-based virtual care provider for higher education serving nearly 500 campuses nationwide, acquired Alongside, a clinician-designed AI coaching platform trusted by more than 200 schools, to expand its student support model with continuous early-intervention AI coaching. TimelyCare has acquired Alongside, a clinician-designed AI coaching platform for students. Alongside combines evidence-based skill-building with proprietary safety models that detect risk and connect students to additional support when needed. Trusted by nearly 500 campuses across the U.S., TimelyCare combines URAC-accredited clinical standards with a measurement-based approach, while Alongside is trusted by more than 200 schools nationwide. The acquisition expands TimelyCare’s approach beyond traditional points of clinical need, positioning the company to engage a broader student population earlier and more consistently across the care continuum. Financial terms were not disclosed. (Link)
  13. Xpress Wellness, a Goldman Sachs-backed Oklahoma City-based provider of urgent care, virtual primary care, occupational medicine, behavioral health and post-acute services, acquired Midwest Counseling Services, a Wichita, Kansas-based mental health clinic founded in 2022 serving older adults in senior communities. Goldman Sachs-backed Xpress Wellness has acquired Wichita-based Midwest Counseling Services. Founded in 2022, Midwest Counseling Services provides mental health services to older adults living in senior communities through approaches including talk therapy and individual counseling. Xpress Wellness is an Oklahoma City-based provider of urgent care, virtual primary care, occupational medicine, behavioral health and post-acute services across rural and suburban communities. Lisa Harrison, founder of Midwest Counseling Services, now serves as Xpress Wellness’ Director of Operations of Post-Acute overseeing the Kansas market, with the deal expanding the acquirer’s behavioral health footprint in Kansas and adjacent states. (Link)
  14. Pediatrica Health Group, a Miami-based multi-site pediatric primary care platform backed by M33 Growth, acquired the long-established Westchester, Miami-Dade pediatric practice of Dr. Juan Ruiz-Unger to expand equitable access to care amid rising regional population growth. Pediatrica Health Group, backed by Boston-based venture and growth-stage investor M33 Growth, has acquired an additional pediatric practice in the Westchester neighborhood of Miami-Dade County. For over 40 years, Dr. Juan Ruiz-Unger has delivered compassionate, evidence-based care to Westchester families. Roberto Palenzuela, Chief Executive Officer of Pediatrica Health Group, said the acquisition aligns with the company’s goal of supporting physicians who want to expand access while maintaining continuity of care within their communities. Financial terms were not disclosed. The deal continues Pediatrica’s multi-site pediatric primary care roll-up strategy across South Florida. (Link)
  15. SpinLife, a Columbus, Ohio-based omni-channel mobility and home accessibility retailer owned by Brentwood, Tennessee-based Complex Rehab Technology leader Numotion, acquired Triton Medical and opened a new SpinLife retail store in Lady Lake, Florida, expanding its Central Florida footprint. Numotion-owned SpinLife has acquired Triton Medical and launched a new Central Florida retail location. SpinLife, owned by Numotion, said in a May 5 announcement that the acquisition was completed on April 22. The retail location is now operating as SpinLife — Lady Lake and strengthens the company’s presence in central Florida and enhancing service to the growing Lady Lake and The Villages communities. Matt Chesshire, Triton Medical’s founder, will remain at the Lady Lake store as general manager. Numotion acquired SpinLife in 2021. Financial terms were not disclosed. (Link)
  16. Care Advantage, Inc., a Mid-Atlantic-based privately held home care provider, announced the acquisition of First Priority Home Care, a Columbia, South Carolina-based non-medical home care agency, advancing its targeted expansion strategy across the Mid-Atlantic and Southeast. Care Advantage, Inc. has acquired Columbia, South Carolina-based First Priority Home Care. Care Advantage, one of the Mid-Atlantic’s largest privately held home care providers, today announced the acquisition of First Priority Home Care, based in Columbia, South Carolina. This latest transaction marks another step in Care Advantage’s continued expansion into the southern United States. First Priority Home Care is a non-medical home care agency based in Columbia, South Carolina, providing in-home support services to seniors and adults who need assistance. Financial terms of the deal were not disclosed. (Link)
  17. Standard Dental Labs Inc., (OTCQB:TUTH) an Orlando-based publicly traded dental laboratory consolidator, completed the acquisition of BRLIT Dental Laboratory, a Sarasota, Florida-based dental lab founded in 1977, adding approximately $886,000 in annual revenue. Standard Dental Labs Inc. (OTCQB: TUTH) has completed the acquisition of BRLIT Dental Laboratory in Sarasota, Florida. The transaction adds approximately $886,000 in annual revenue to Standard Dental Labs’ existing revenue base of approximately $236,000, bringing the company’s total annualized revenue to more than $1.1 million. The company holds a market capitalization of $6.54 million. BRLIT Dental Laboratory, founded in 1977, has served dentists throughout Florida for nearly five decades, and the acquisition expands the buyer’s footprint along Florida’s Gulf Coast. The company intends to continue pursuing strategic acquisitions in Florida’s dental laboratory industry. (Link)
  18. TopGum Industries Ltd. (TASE: TPGM), an Israel-based global leader in gummy-format dietary supplements, completed the acquisition of the U.S. gummy manufacturing operations of P&L Developments LLC, a Westbury, New York-based pharmaceutical and consumer healthcare CDMO, in a transaction valued at up to USD 35 million. TopGum Industries Ltd. (TASE: TPGM) has completed its acquisition of P&L Developments’ U.S. gummy manufacturing operations. The consideration, funded by TopGum’s existing resources, comprises US$10 million in cash at closing, 1,893,060 shares valued at approximately US$8 million at closing (based on a price of NIS 13 per share), and up to 4,022,751 additional shares (valued at up to US$17 million) as contingent consideration, payable upon achievement of agreed commercial and regulatory milestones.  (Link)
  19. Arete Health Announces Acquisitions of Virginia Rehabilitation & Wellness and Summerville Physical Therapy & Balance for Adults Arete Health, a physician-led multi-specialty practice management platform, acquired Virginia Rehabilitation & Wellness and Summerville Physical Therapy & Balance for Adults, two established physical therapy practices in Virginia. Arete Health has completed the acquisition of two Virginia-based physical therapy practices—Virginia Rehabilitation & Wellness and Summerville Physical Therapy & Balance for Adults—on May 5, 2026. The deals strengthen Arete’s outpatient rehabilitation footprint in the Mid-Atlantic and add specialized orthopedic, sports medicine, and balance therapy services. The combined practices serve several hundred patients weekly across multiple locations. Financial terms were not disclosed. (Link)

Venture Deals and Other

  1. Basata, a Phoenix-based AI company building the operational layer for U.S. healthcare, raised a $21 million Series A led by Basis Set Ventures with participation from Cowboy Ventures, PHX Ventures, Zenda Capital, and Victoria Treyger, bringing total funding to $24.5 million. Basata has closed a $21 million Series A funding round to scale its AI-driven healthcare administrative automation platform. The Series A was led by Basis Set Ventures, with participation from Cowboy Ventures, PHX Ventures, Zenda Capital, and Victoria Treyger. The round brings total funding to $24.5 million. Basis Set Ventures’ Lan Xuezhao led the round, joined by Cowboy Ventures’ Aileen Lee, PHX Ventures, Zenda Capital, and Victoria Treyger. The company has served more than 500,000 patients to date, including 100,000 patients during the past month alone, while working with specialty groups across cardiology, urology, gastroenterology, and ophthalmology. (Link)
  2. Dandelion Health, a New York-based clinical intelligence platform serving life sciences, raised a $14 million Series A led by Healthier Capital with participation from Colle Capital and existing investors Primary Venture Partners, Moxxie Ventures, and Convergent Ventures, to scale its multimodal clinical AI infrastructure. Dandelion Health has secured $14 million in Series A funding. Healthier Capital led the round, with participation from Colle Capital and existing investors Moxxie Ventures, Convergent Ventures and Primary Venture Partners. Built on a network spanning 73 hospitals and more than 15 million patients, Dandelion is unique in its ability to combine structured data — electronic medical records and claims — with unstructured clinical text and raw biological signals including ECG waveforms, echocardiogram videos, radiology imaging, pulmonary function tests, and ultrasound. The Series A financing will be used to expand Dandelion’s pharmaceutical partnerships, scale the company’s data and engineering infrastructure, and grow commercial and scientific teams. (Link)
  3. Enzo Health, a Lehi, Utah-based AI-driven platform for home health and post-acute care launched in 2024, raised a $20 million Series A led by global venture capital firm N47 with participation from existing investors Gradient (a Google-affiliated investment firm), Tandem Ventures, and Rigby Watts, bringing total funding to $26 million. Enzo Health has raised a $20 million Series A funding round. The round was led by N47, bringing the company’s total funding to $26M. Existing investors Gradient, Tandem Ventures, and Rigby Watts also participated. Existing investors Gradient (Palo Alto, a Google-affiliated investment firm), Tandem Ventures (Draper, UT), and Rigby Watts (Millcreek, UT) also participated. Launched in 2024, Enzo Health has grown revenue by more than 40X in twelve months and is now used by organizations that support over 500,000 patients annually. The funds will accelerate expansion into skilled nursing and hospice sectors. (Link)
  4. Travv, a Stillwater, Oklahoma-based AI-native diagnostic platform for veterinary medicine led by founder and CEO Derick Whitley, DVM, DACVP, closed a $1.6 million seed funding round led by Digitalis Ventures with participation from AniVC, to advance its cloud-based veterinary diagnostic platform. Travv has closed a $1.6 million seed funding round. Travv, a Stillwater, OK-based provider of an AI-native diagnostic platform for veterinary medicine, closed a $1.6m seed funding round. The round was led by Digitalis Ventures, with participation from AniVC. The funding will support continued development of Travv’s AI-native diagnostic platform for veterinary medicine, including product expansion, hospital onboarding, commercial growth, and key integrations. Digitalis Ventures backs founders solving critical problems in health. The firm invests in early-stage companies across life sciences, health technology & services, and animal health, while AniVC focuses on early-stage pet companies. (Link)